{
  "letters": 549905,
  "pages": 143,
  "meta": {
    "end_of_period": {
      "year": 2022,
      "month": 12
    },
    "company_name": "NeoGenomics, Inc.",
    "major_industry": "Healthcare",
    "mentions_recent_mergers_and_acquisitions": {
      "value": true,
      "elements": [
        {
          "type": "merger_acquisition",
          "page": 35,
          "title": "Acquisition Integration and Associated Risks",
          "data": [
            {
              "key": "integration_risk",
              "value": "Potential inability to successfully combine the acquired company’s business with our legacy business."
            },
            {
              "key": "cost_synergies",
              "value": "Uncertainty whether the expected cost synergies and other anticipated benefits will be achieved."
            },
            {
              "key": "system_consolidation",
              "value": "Challenges related to consolidating critical systems such as laboratory information and billing systems."
            },
            {
              "key": "diversification_strategy",
              "value": "Difficulties in executing a strategy to achieve revenue growth by cross-selling products and services across an expanded portfolio."
            },
            {
              "key": "operational_assumptions",
              "value": "The need to revisit assumptions regarding reserves, revenues, capital expenditures, and operating costs."
            },
            {
              "key": "management_distraction",
              "value": "Risk that the integration process may divert management’s attention, potentially affecting relationships with customers, employees, and partners."
            },
            {
              "key": "key_assets_retention",
              "value": "Potential loss of key employees, customers, contracts, and strategic partners which could affect integration and ongoing operations."
            },
            {
              "key": "integration_complexity",
              "value": "Complexities associated with managing distinct corporate cultures, systems, and internal controls during the integration."
            },
            {
              "key": "goodwill_impairment",
              "value": "Risk of significant charges against earnings if goodwill and intangible assets recorded in connection with acquisitions become impaired."
            },
            {
              "key": "additional_costs",
              "value": "Possibility of incurring greater transaction and integration costs than initially anticipated."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 42,
          "title": "Table of Contents Analysis",
          "data": [
            {
              "key": "Company",
              "value": "NEOGENOMICS, INC."
            },
            {
              "key": "Acquisition",
              "value": "The acquisition of Inivata, which enhanced oncology Liquid Biopsy technology capabilities."
            },
            {
              "key": "Liquid Biopsy Assays",
              "value": "InVisionFirst -Lung for plasma-based NSCLC testing and RaDaR for detecting residual disease and recurrence."
            },
            {
              "key": "Molecular Panels",
              "value": "Comprehensive panels that integrate DNA and RNA testing to report a full spectrum of genomic alterations."
            },
            {
              "key": "Pharma Services",
              "value": "Includes revenue streams from clinical trials and research, validation laboratory services, and informatics, supporting companion diagnostic development and FDA submissions."
            },
            {
              "key": "Service Offering",
              "value": "Combination of technical and professional components in molecular testing and pathology interpretation services."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 43,
          "title": "Table of Contents & Critical Accounting Policies Overview",
          "data": [
            {
              "key": "Company",
              "value": "NEOGENOMICS, INC."
            },
            {
              "key": "Investments and Tools",
              "value": "Invested in leading technologies; developing informatics and data-related tools to leverage market position and oncology expertise"
            },
            {
              "key": "Product Highlight",
              "value": "Trapelo™ – an end-to-end clinical decision-support platform for precision oncology"
            },
            {
              "key": "Critical Accounting Policies",
              "value": "Includes Business Combinations, Accounts Receivable, Recoverability and Impairment of Long-Lived Assets, Goodwill, Contingencies, Stock-based Compensation, Revenue Recognition, and Deferred Taxes"
            },
            {
              "key": "Business Combinations",
              "value": "Acquired companies' operations and cash flows are integrated from the date of acquisition; purchase price allocation to assets and liabilities, with excess recorded as goodwill; transaction costs expensed as incurred"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 66,
          "title": "Valuation Assumptions and Financial Instruments",
          "data": [
            {
              "key": "purchase price allocations",
              "value": "Could result in different allocations and amortization."
            },
            {
              "key": "transaction costs",
              "value": "Associated with acquisitions, expensed as incurred."
            },
            {
              "key": "financial instruments",
              "value": "Measured at fair value on a recurring basis."
            },
            {
              "key": "cash equivalents",
              "value": "Considered as investments with maturity of ninety days."
            },
            {
              "key": "marketable securities",
              "value": "Classified as available-for-sale."
            },
            {
              "key": "temporary impairments",
              "value": "Evaluated quarterly for other-than-temporary impairment."
            },
            {
              "key": "credit risks",
              "value": "Concentration not considered significant."
            },
            {
              "key": "accounts receivable",
              "value": "Reported based on expected collections considering concessions."
            },
            {
              "key": "inventories",
              "value": "Valued at lower of cost or net realizable value."
            },
            {
              "key": "prepaid assets",
              "value": "Included within current assets."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 72,
          "title": "Note 3. Acquisitions Trapelo Health",
          "data": [
            {
              "key": "Acquisition Date",
              "value": "April 7, 2021"
            },
            {
              "key": "Acquired Entity",
              "value": "Trapelo Health (Intervention Insights, Inc. d/b/a Trapelo Health)"
            },
            {
              "key": "Transaction Description",
              "value": "Business combination acquisition of 100% ownership interest in Trapelo Health, an information technology company focused on precision oncology."
            },
            {
              "key": "Cash Consideration",
              "value": "$35.6 million (includes a net adjustment of $0.6 million for cash on hand and working capital adjustments)"
            },
            {
              "key": "Equity Consideration",
              "value": "$29.2 million (597,712 shares of common stock at $48.81 per share)"
            },
            {
              "key": "Total Purchase Consideration",
              "value": "$64,765 thousand"
            },
            {
              "key": "Breakdown of Consideration",
              "value": "Common stock issued valued at $29,174 thousand and cash paid of $35,591 thousand"
            },
            {
              "key": "Allocation - Developed Technology",
              "value": "$19,040 thousand (valued using income approach - multi-period excess earnings method)"
            },
            {
              "key": "Allocation - Marketing Intangible Assets",
              "value": "$549 thousand (valued using income approach - relief from royalty method)"
            },
            {
              "key": "Net Identifiable Assets Acquired",
              "value": "$20,101 thousand"
            },
            {
              "key": "Goodwill",
              "value": "$44,664 thousand"
            },
            {
              "key": "Weighted-Average Amortization Period",
              "value": "9.8 years"
            },
            {
              "key": "Valuation Measurement",
              "value": "Level 3 measurements based on unobservable inputs and significant management estimates"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 73,
          "title": "Acquisitions of Trapelo and Inivata",
          "data": [
            {
              "key": "Goodwill Recognized",
              "value": "Attributed to expected synergies of combined businesses and an assembled workforce in the Clinical Services segment; note that goodwill from Trapelo is not expected to be tax deductible."
            },
            {
              "key": "Trapelo Acquisition Costs",
              "value": "Approximately $1.8 million in acquisition and integration costs for year ended December 31, 2021, recorded as general and administrative expenses."
            },
            {
              "key": "Trapelo Financial Impact",
              "value": "Results of operations of Trapelo not material from acquisition date to December 31, 2021; no pro forma adjustments provided."
            },
            {
              "key": "Inivata Acquisition Date",
              "value": "June 18, 2021"
            },
            {
              "key": "Inivata Business Description",
              "value": "A global, commercial stage, liquid biopsy platform company, adding minimal residual disease testing capabilities."
            },
            {
              "key": "Inivata Purchase Details",
              "value": "Acquisition of remaining equity interests; purchase price of $398.6 million (cash consideration with adjustments), funded through cash on hand and private placement of equity."
            },
            {
              "key": "Equity Investment and Option",
              "value": "Previously held $25.0 million minority equity investment, with a fixed price Purchase Option valued at $74.3 million, along with a $64.9 million fair value of Preference Shares."
            },
            {
              "key": "Line of Credit",
              "value": "A $15.0 million line of credit was settled as part of the acquisition, with an outstanding amount of $10.3 million recorded at the acquisition date."
            },
            {
              "key": "Gain on Investment",
              "value": "A gain of $109.3 million recorded from the excess of the fair value of the previously-held equity interest, Purchase Option, and Line of Credit over their carrying values."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 75,
          "title": "Acquisition of Inivata and Pro Forma Financial Results",
          "data": [
            {
              "key": "Acquisition Price",
              "value": "$56.6 million"
            },
            {
              "key": "Goodwill Tax Deductibility",
              "value": "None of the goodwill from the acquisition of Inivata is expected to be deductible for income tax purposes"
            },
            {
              "key": "Acquisition and Integration Costs (2021)",
              "value": "$13.9 million incurred for the year ended December 31, 2021, recorded as general and administrative expenses"
            },
            {
              "key": "Cost Record in Other Years",
              "value": "No similar costs recorded for the years ended December 31, 2022 and 2020"
            },
            {
              "key": "Inivata Subsidiary Revenue",
              "value": "$1.5 million recorded in Pharma Services revenue from the Inivata Acquisition Date to December 31, 2021"
            },
            {
              "key": "Inivata Subsidiary Net Loss",
              "value": "$27.6 million for the period from the Inivata Acquisition Date to December 31, 2021"
            },
            {
              "key": "Pro Forma Net Revenue (2020)",
              "value": "$444,884"
            },
            {
              "key": "Pro Forma Net Revenue (2021)",
              "value": "$484,231"
            },
            {
              "key": "Pro Forma Net Loss (2020)",
              "value": "$(65,387)"
            },
            {
              "key": "Pro Forma Net Loss (2021)",
              "value": "$(129,251)"
            },
            {
              "key": "Inivata Acquisition Transaction Costs",
              "value": "$11.0 million (incurred by Inivata, included in net loss as if incurred on January 1, 2020)"
            },
            {
              "key": "Company Transaction and Retention Costs",
              "value": "$13.9 million (incurred by the Company, included in net loss as if incurred on January 1, 2020)"
            },
            {
              "key": "Excluded Gain on Investment and Loan Receivable from Non-Consolidated Affiliate (2021)",
              "value": "$109.3 million"
            },
            {
              "key": "Excluded Gain on Investment and Loan Receivable from Non-Consolidated Affiliate (2020)",
              "value": "$4.0 million"
            },
            {
              "key": "Pro Forma Summary",
              "value": "Net revenue increased from 2020 to 2021, but net losses more than doubled, indicating deteriorating bottom-line performance despite revenue growth."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 82,
          "title": "Investment Agreement and Acquisition of Inivata",
          "data": [
            {
              "key": "Company",
              "value": "NEOGENOMICS, INC."
            },
            {
              "key": "Investment",
              "value": "Investment Agreement with Inivata"
            },
            {
              "key": "Amount",
              "value": "$25.0 million"
            },
            {
              "key": "Equity Interest",
              "value": "minority interest in Inivata’s outstanding equity"
            },
            {
              "key": "Date of Acquisition Completion",
              "value": "June 18, 2021"
            },
            {
              "key": "Board Representation",
              "value": "one seat on Inivata’s Board of Directors"
            },
            {
              "key": "Initial Cost Allocated",
              "value": "$25.0 million"
            },
            {
              "key": "Preference Shares Value",
              "value": "$19.6 million"
            },
            {
              "key": "Purchase Option Value",
              "value": "$6.0 million"
            },
            {
              "key": "Remeasurement Value at December 31, 2020",
              "value": "$29.6 million"
            },
            {
              "key": "Net Unrealized Gain Year 2020",
              "value": "$4.0 million"
            },
            {
              "key": "Line of Credit Amount",
              "value": "$15.0 million"
            },
            {
              "key": "Present Value of Loan Receivable",
              "value": "$10.0 million"
            },
            {
              "key": "Carrying Value as of March 31, 2021",
              "value": "$29.6 million"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 83,
          "title": "Inivata Acquisition Details",
          "data": [
            {
              "key": "Acquisition Date",
              "value": "TBD"
            },
            {
              "key": "Acquisition Method",
              "value": "Business combination achieved in stages"
            },
            {
              "key": "Carrying Value of Investment",
              "value": "$29.6 million"
            },
            {
              "key": "Preference Shares Value",
              "value": "$25.0 million"
            },
            {
              "key": "Purchase Option Value",
              "value": "$4.6 million"
            },
            {
              "key": "Fair Value of Preference Shares",
              "value": "$64.9 million"
            },
            {
              "key": "Fair Value of Purchase Option",
              "value": "$74.3 million"
            },
            {
              "key": "Net Gain for Year",
              "value": "$104.6 million"
            },
            {
              "key": "Outstanding Line of Credit",
              "value": "$10.3 million"
            },
            {
              "key": "Effective Settlement Amount",
              "value": "$15.0 million"
            },
            {
              "key": "Gain from Settlement",
              "value": "$4.7 million"
            },
            {
              "key": "Total Gain on Investment",
              "value": "$109.3 million"
            },
            {
              "key": "Reporting Period",
              "value": "Year ended December 31, 2021"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 84,
          "title": "2028 Convertible Notes Indenture Overview",
          "data": [
            {
              "key": "Date of Indenture",
              "value": "January 11, 2021"
            },
            {
              "key": "Trustee",
              "value": "U.S. Bank National Association"
            },
            {
              "key": "Total Principal Amount",
              "value": "$1,000"
            },
            {
              "key": "Conversion Rate",
              "value": "15.1172 shares of common stock per $1,000"
            },
            {
              "key": "Initial Conversion Price",
              "value": "$66.15 per share"
            },
            {
              "key": "Latest Closing Stock Price",
              "value": "$9.24 as of December 31, 2022"
            },
            {
              "key": "Redemption Start Date",
              "value": "January 20, 2025"
            },
            {
              "key": "Redemption Price",
              "value": "100% of principal plus accrued interest"
            },
            {
              "key": "Conditions for Conversion",
              "value": "Specific trading conditions and corporate events must be met."
            },
            {
              "key": "Bankruptcy Clause",
              "value": "Principle and interest become due upon bankruptcy."
            },
            {
              "key": "Conversion Notices Received",
              "value": "None as of December 31, 2022"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 128,
          "title": "Assignment, Severability, and Arbitration Provisions",
          "data": [
            {
              "key": "Cost Reimbursement",
              "value": "The Company shall bear all costs reasonably incurred by the Tax Counsel."
            },
            {
              "key": "Assignment Clause",
              "value": "Neither the Executive nor the Company may assign the Agreement without prior written consent, except that the Company may assign its rights and obligations in connection with a reorganization, consolidation, merge, or transfer of substantially all of its properties or assets."
            },
            {
              "key": "Severability",
              "value": "If any provision is declared illegal or unenforceable, the remainder of the Agreement remains effective."
            },
            {
              "key": "Entire Agreement & Modification",
              "value": "This Agreement embodies the entire understanding between the Executive and the Company and can only be modified in writing by both parties."
            },
            {
              "key": "Governing Law & Arbitration",
              "value": "The Agreement is governed by Florida law, with disputes to be resolved by arbitration in Fort Myers, Lee County, Florida."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_leadership_changes": {
      "value": true,
      "elements": [
        {
          "type": "leadership_change",
          "page": 40,
          "title": "Overview and Highlights",
          "data": [
            {
              "key": "Consolidated Revenue Growth",
              "value": "Increased by 5.2% compared to 2021"
            },
            {
              "key": "Clinical Services Revenue Growth",
              "value": "3.6% increase"
            },
            {
              "key": "Pharma Services Revenue Growth",
              "value": "13.5% increase"
            },
            {
              "key": "Quarterly Performance",
              "value": "Revenue, gross margin and adjusted EBITDA growth reported sequentially in each quarter of 2022"
            },
            {
              "key": "Leadership Appointments",
              "value": "Welcomed Chris Smith (Chief Executive Officer), Jeff Sherman (Chief Financial Officer), Warren Stone (President, Clinical Services), Vishal Sikri (President, Pharma Services and President and Chief Commercial Officer, Inivata), and Melody Harris (President, Enterprise Operations)"
            },
            {
              "key": "Corporate Vision",
              "value": "Developed 'OneNeo' to integrate the company and align core capabilities"
            },
            {
              "key": "Restructuring Effort",
              "value": "Initiated effort to reduce significant costs in 2023"
            },
            {
              "key": "New Diagnostic Launch",
              "value": "Accelerate Advanced Diagnostics with clinical RaDaR™ (MRD) launch"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 104,
          "title": "NeoGenomics, Inc. Corporate Agreements and Filings Reference Table",
          "data": [
            {
              "key": "Separation Agreement",
              "value": "Dated March 28, 2022 between NeoGenomics, Inc. and Mark Mallon; Incorporated by reference to the Company's Current Report on Form 8-K."
            },
            {
              "key": "Executive Chair and Principal Executive Officer Agreement",
              "value": "Dated April 25, 2022 between NeoGenomics, Inc. and Lynn A. Tetrault; Incorporated by reference to the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2022, filed on May 9, 2022."
            },
            {
              "key": "Employment Agreement",
              "value": "Executed July 20, 2022 between NeoGenomics, Inc. and Christopher Smith; Incorporated by reference to the Company's Current Report on Form 8-K filed on July 21, 2022."
            },
            {
              "key": "Employment Agreement",
              "value": "Dated November 2, 2022 between NeoGenomics, Inc. and Warren Stone; Document provided directly."
            },
            {
              "key": "Employment Agreement",
              "value": "Dated November 14, 2022 between NeoGenomics, Inc. and Melody Harris; Document provided directly."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 106,
          "title": "Signature Block",
          "data": [
            {
              "key": "By",
              "value": "/s/ Christopher M. Smith"
            },
            {
              "key": "Name",
              "value": "Christopher M. Smith"
            },
            {
              "key": "Title",
              "value": "Director and Chief Execut"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 106,
          "title": "Board of Directors and Executive Officers Signatures",
          "data": [
            {
              "key": "Christopher M. Smith",
              "value": "Director and Chief Executive Officer, Principal Executive Officer, February 24, 2023"
            },
            {
              "key": "Jeffrey S. Sherman",
              "value": "Chief Financial Officer (Principal Financial Officer), February 24, 2023"
            },
            {
              "key": "Cynthia J. Dieter",
              "value": "Chief Accounting Officer, Principal Accounting Officer, February 24, 2023"
            },
            {
              "key": "Lynn A. Tetrault",
              "value": "Chair of the Board, February 24, 2023"
            },
            {
              "key": "Bruce K. Crowther",
              "value": "Director, February 24, 2023"
            },
            {
              "key": "Dr. Alison L. Hannah",
              "value": "Director, February 24, 2023"
            },
            {
              "key": "Stephen M. Kanovsky",
              "value": "Director, February 24, 2023"
            },
            {
              "key": "Michael A. Kelly",
              "value": "Director, February 24, 2023"
            },
            {
              "key": "David B. Perez",
              "value": "Director, February 24, 2023"
            },
            {
              "key": "Rachel A. Stahler",
              "value": "Director, February 24, 2023"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 107,
          "title": "Exhibit 10.18 EMPLOYMENT AGREEMENT",
          "data": [
            {
              "key": "Agreement Date",
              "value": "November 2, 2022"
            },
            {
              "key": "Commencement Date",
              "value": "November 21, 2022"
            },
            {
              "key": "Company",
              "value": "NeoGenomics, Inc."
            },
            {
              "key": "Executive",
              "value": "Warren Stone"
            },
            {
              "key": "Position",
              "value": "Division President, Clinical Services"
            },
            {
              "key": "Subsidiary",
              "value": "NeoGenomics Laboratories, Inc."
            },
            {
              "key": "Reporting",
              "value": "Reports to the Company's Chief Executive Officer"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 118,
          "title": "Agreement Execution Signature Block",
          "data": [
            {
              "key": "Executive Signature",
              "value": "Warren Stone"
            },
            {
              "key": "Company Representative Signature",
              "value": "Chris Smith"
            },
            {
              "key": "Company Representative Title",
              "value": "Chief Executive Officer"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 119,
          "title": "Exhibit 10.19 EMPLOYMENT AGREEMENT",
          "data": [
            {
              "key": "Agreement Date",
              "value": "November 14, 2022"
            },
            {
              "key": "Commencement Date",
              "value": "December 5, 2022"
            },
            {
              "key": "Company",
              "value": "NeoGenomics, Inc."
            },
            {
              "key": "Executive",
              "value": "Melody Harris"
            },
            {
              "key": "Position",
              "value": "President, Enterprise Operations"
            },
            {
              "key": "Principal Place of Employment",
              "value": "Denver, Colorado"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 130,
          "title": "Leadership Change Agreement",
          "data": [
            {
              "key": "Executive Name",
              "value": "Melody Harris"
            },
            {
              "key": "Company Representative Name",
              "value": "Chris Smith"
            },
            {
              "key": "Company Representative Title",
              "value": "Chief Executive Officer"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 138,
          "title": "Subsidiaries of NeoGenomics, Inc.",
          "data": [
            {
              "key": "Subsidiary Names",
              "value": "Clarient Diagnostic Services, Inc., Clarient, Inc., Cynogen, Inc., Genesis Acquisition Holdings Corp., Genoptix, Inc., Inivata Limited, Inivata, Inc., Minuet Diagnostics, Inc., NeoGenomics Bioinformatics, Inc., NeoGenomics Europe, SA, NeoGenomics Foundation, Inc., NeoGenomics Laboratories, Inc., NeoGenomics Singapore, Pte. Ltd., Suzhou NeoGenomics Pharmaceutical Research Co., Limited, Trapelo Health, LLC"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 141,
          "title": "Certifications by CFO",
          "data": [
            {
              "key": "CFO Name",
              "value": "Jeffrey S. Sherman"
            },
            {
              "key": "Position",
              "value": "Chief Financial Officer"
            },
            {
              "key": "Certification Date",
              "value": "February 24, 2023"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 142,
          "title": "Certification Pursuant to 18 U.S.C. Section 1350",
          "data": [
            {
              "key": "Company Name",
              "value": "NeoGenomics, Inc."
            },
            {
              "key": "Report Type",
              "value": "Annual Report Form 10-K"
            },
            {
              "key": "Fiscal Year End Date",
              "value": "December 31, 2022"
            },
            {
              "key": "Date of Certification",
              "value": "February 24, 2023"
            },
            {
              "key": "CEO Name",
              "value": "Christopher M. Smith"
            },
            {
              "key": "CFO Name",
              "value": "Jeffrey S. Sherman"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_layoffs": {
      "value": true,
      "elements": [
        {
          "type": "layoff",
          "page": 81,
          "title": "Intangible Assets and Amortization Schedule",
          "data": [
            {
              "key": "Total cost of intangible assets",
              "value": "$501,380"
            },
            {
              "key": "Total accumulated amortization",
              "value": "$93,120"
            },
            {
              "key": "Net value",
              "value": "$408,260"
            },
            {
              "key": "Significant asset categories",
              "value": "Customer Relationships, Developed Technology, Marketing Assets, Trademarks, Trade Names"
            },
            {
              "key": "Largest asset category",
              "value": "Developed Technology"
            },
            {
              "key": "Amortization periods range",
              "value": "2.5 to 15 years"
            },
            {
              "key": "Indefinite-lived trademark",
              "value": "Trademark - Indefinite lived"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "layoff",
          "page": 81,
          "title": "Amortization Breakdown",
          "data": [
            {
              "key": "Cost of revenue amortization",
              "value": "$19,412"
            },
            {
              "key": "General and administrative amortization",
              "value": "$14,646"
            },
            {
              "key": "Total amortization",
              "value": "$34,058"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "layoff",
          "page": 81,
          "title": "Future Amortization Expenses",
          "data": [
            {
              "key": "2023",
              "value": "$35,133"
            },
            {
              "key": "2024",
              "value": "$33,446"
            },
            {
              "key": "2025",
              "value": "$33,343"
            },
            {
              "key": "2026",
              "value": "$33,308"
            },
            {
              "key": "2027",
              "value": "$32,758"
            },
            {
              "key": "Total future amortization",
              "value": "$394,813"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "layoff",
          "page": 133,
          "title": "Separation Agreement and Release of Claims",
          "data": [
            {
              "key": "Employee Status",
              "value": "Termination effective upon Separation Date."
            },
            {
              "key": "Compensation and Benefits",
              "value": "No further compensation or benefits provided after Separation Date."
            },
            {
              "key": "Employee Benefits",
              "value": "Participation in employee benefit plans ends as of Separation Date."
            },
            {
              "key": "COBRA Rights",
              "value": "Eligibility to continue participation in group health plans."
            },
            {
              "key": "Expense Reimbursement",
              "value": "Final expense reimbursement statement due within sixty days post-Separation."
            },
            {
              "key": "Indemnification Agreement",
              "value": "Indemnification Agreement remains in effect post-Separation."
            },
            {
              "key": "Confidentiality Obligations",
              "value": "Continued obligation to comply with Confidentiality, Non-Solicitation, and Non-Compete Agreement."
            },
            {
              "key": "Transition Duties",
              "value": "Obligation to assist in transition of duties to Company designees."
            },
            {
              "key": "Non-Disparagement Clause",
              "value": "Agreement not to disparage the Company or its affiliates."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "layoff",
          "page": 134,
          "title": "General Release and Waiver of Claims",
          "data": [
            {
              "key": "Significance",
              "value": "Agreement entails an employee's acknowledgment and agreement regarding the return of company property and the release of claims against the company."
            },
            {
              "key": "Context",
              "value": "Discussion of employee termination and associated severance benefits."
            },
            {
              "key": "Legal References",
              "value": "Agreements related to various employment and anti-discrimination laws."
            },
            {
              "key": "Obligations",
              "value": "Employee agrees to refrain from making disparaging comments and to return company documents and property."
            },
            {
              "key": "Separation Date",
              "value": "End of employment and associated responsibilities outlined."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "layoff",
          "page": 135,
          "title": "Release of Claims Agreement",
          "data": [
            {
              "key": "Content",
              "value": "administrators, trustees, agents, representatives, predecessors, successors and assigns, and all others connected with any of them, both individually and in their official capacities, from, and you hereby waive, any and all such Claims. Notwithstanding the foregoing, 'Claims' does not include any claims (i) for unemployment benefits or (ii) that cannot be released as a matter of law. (b) Nothing in this Agreement shall be construed to prohibit you from filing a charge with or participating in any investigation or proceeding conducted by the federal Equal Employment Opportunity Commission or a comparable state or local agency; provided, however, that you hereby agree to waive your right to recover monetary damages or other personal relief in any such charge, investigation or proceeding, or in any related complaint or lawsuit, filed by you or by anyone else on your behalf. Nothing in this Agreement limits, restricts or in any other way affects your communicating with any governmental agency or entity, or communicating with any official or staff person of a governmental agency or entity, concerning matters relevant to such governmental agency or entity. (c) Notwithstanding the generality of the foregoing, you do not release the following causes of actions, rights and claims: (i) a claim for enforcement of this Agreement; (ii) claims for unemployment compensation or workers’ compensation benefits pursuant to the terms of applicable law or policy; (iii) your rights pursuant to the terms and conditions of COBRA; or (iv) your rights and claims for indemnification and/or defense pursuant to the terms of the Company’s organizing and corporate documents, liability insurance policies, or applicable law. (d) This Agreement, including the general release and waiver of claims set forth in this Section 8, creates legally binding obligations and the Company and its Affiliates therefore advise you to consult an attorney before signing this Agreement. In signing this Agreement, you give the Company and its Affiliates assurance that you have signed it voluntarily and with a full understanding of its terms; that you have had sufficient opportunity of not less than twenty-one (21) days, before signing it, to consider its terms and to consult with an attorney, if you wished to do so; and that you have not relied on any promises or representations, express or implied, that are not set forth expressly in this Agreement."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "layoff",
          "page": 137,
          "title": "Separation Agreement Terms",
          "data": [
            {
              "key": "Company",
              "value": "NEOGENOMICS, INC."
            },
            {
              "key": "Signatory",
              "value": "Chris Smith"
            },
            {
              "key": "Title",
              "value": "Chief Executive Officer"
            },
            {
              "key": "Accepted by",
              "value": "William Bonello"
            },
            {
              "key": "Date Signed",
              "value": "December 21, 2022"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_executive_compensation": {
      "value": true,
      "elements": [
        {
          "type": "executive_compensation",
          "page": 2,
          "title": "NEOGENOMICS, INC. FORM 10-K ANNUAL REPORT - Table of Contents",
          "data": [
            {
              "key": "Row 1",
              "value": "RTI ii.: LIA. - Business: Factors"
            },
            {
              "key": "Row 2",
              "value": "RTI ii.: 1B. - Business: Unresolved Staff Comments"
            },
            {
              "key": "Row 3",
              "value": "RTI ii.: 12. - Business: Properties"
            },
            {
              "key": "Row 4",
              "value": "RTI ii.: 13. - Business: Proceedings"
            },
            {
              "key": "Row 5",
              "value": "RTI ii.: 14. - Business: Safety Disclosures"
            },
            {
              "key": "Row 6",
              "value": "RTI ii.: RT - Business: RT"
            },
            {
              "key": "Row 7",
              "value": "RTI ii.: 15. - Business: Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities"
            },
            {
              "key": "Row 8",
              "value": "RTI ii.: 16. - Business: Selected Financial Data"
            },
            {
              "key": "Row 9",
              "value": "RTI ii.: 17. - Business: Management's Discussion and Analysis of Financial Condition and Results of Operations"
            },
            {
              "key": "Row 10",
              "value": "RTI ii.: 19. - Business: Changes in and Disagreements With Accountants on Accounting and Financial Disclosure"
            },
            {
              "key": "Row 11",
              "value": "RTI ii.: 9A. 9B. - Business: Controls and Procedures Information"
            },
            {
              "key": "Row 12",
              "value": "RTI ii.: RT UT - Business: "
            },
            {
              "key": "Row 13",
              "value": "RTI ii.: 110. - Business: Directors, Executive Officers and Corporate Governance"
            },
            {
              "key": "Row 14",
              "value": "RTI ii.: iit. - Business: Executive Compensation"
            },
            {
              "key": "Row 15",
              "value": "RTI ii.: 112. - Business: Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters"
            },
            {
              "key": "Row 16",
              "value": "RTI ii.: 113. - Business: Certain Relationships and Related Transactions, and Director Independence"
            },
            {
              "key": "Row 17",
              "value": "RTI ii.: 114. - Business: Principal Accounting Fees and Services"
            },
            {
              "key": "Row 18",
              "value": "RTI ii.: RT IV - Business: "
            },
            {
              "key": "Row 19",
              "value": "RTI ii.: 115. - Business: Exhibits and Financial Statement Schedules 10-K"
            },
            {
              "key": "Row 20",
              "value": "RTI ii.: 116. - Business: Summary"
            },
            {
              "key": "Row 21",
              "value": "RTI ii.: NATURES - Business: "
            },
            {
              "key": "Additional Text",
              "value": "PART I Item 1. Item 1A. Item 1B. Jtem2. Item 3. Item 4. PART II Item 5. Item 6. Item 7. Item 7A. Item 8. Item 9. Item 9A. Item 9B. Item 9C. PART III Item 10. Item 11. Item 12. Item 13. Item 14. PART IV Item 15. Item 16. SIGNATURES 2"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 37,
          "title": "Equity Compensation Plans Overview",
          "data": [
            {
              "key": "Table Summary",
              "value": "This table presents details of equity compensation plans, both approved and not approved by security holders. The Equity Incentive Plan has 3,271,004 securities to be issued at an average price of 17.67, with 4,868,198 securities remaining available. The Employee Stock Purchase Plan (ESPP) has 709,107 securities remaining available. Inducement Awards include 943,613 securities to be issued at an average price of 12.36."
            },
            {
              "key": "Equity Compensation Plan - Approved",
              "value": "Equity Incentive Plan and Employee Stock Purchase Plan (ESPP) have been approved by security holders. The Equity Incentive Plan was approved on multiple occasions, most recently on May 27, 2021 with an increased share reserve of 25,625,000."
            },
            {
              "key": "Equity Compensation Plan - Not Approved",
              "value": "Inducement Awards, which are not approved by security holders."
            },
            {
              "key": "Amended and Restated Equity Incentive Plan",
              "value": "Securities to be issued: 3271004, Weighted Average Exercise Price: 17.67, Securities Remaining: 4868198"
            },
            {
              "key": "Employee Stock Purchase Plan (ESPP)",
              "value": "Securities to be issued: N/A, Weighted Average Exercise Price: N/A, Securities Remaining: 709107"
            },
            {
              "key": "Inducement Awards",
              "value": "Securities to be issued: 943613, Weighted Average Exercise Price: 12.36, Securities Remaining: N/A"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 69,
          "title": "Table of Contents",
          "data": [
            {
              "key": "Debt Issuance Costs",
              "value": "Costs related to convertible senior notes, term loans, and lines of credit are recorded differently: as deductions from the principal or as assets, and are amortized as interest expense using the effective interest method."
            },
            {
              "key": "Stock-based Compensation",
              "value": "Compensation expense for stock-based awards to employees, non-employee contracted physicians, and directors is measured based on grant-date fair values. The Company transitioned in 2021 from a trinomial lattice model to the Black-Scholes option valuation model, using assumptions such as expected term, risk-free interest rate, expected volatility, and a zero dividend yield."
            },
            {
              "key": "Revenue Recognition - Clinical Services",
              "value": "Diagnostic services are performed based on written or electronic test requisitions, with revenue recognized at the point of service delivery. Billing to multiple payers takes into account implicit price concessions reflecting discounts and expected adjustments."
            },
            {
              "key": "Revenue Recognition - Pharma Services",
              "value": "Services for pharmaceutical and biotech customers, including clinical trial and research services, are recorded on a unit-of-service basis. Some contracts include upfront fees or billing milestones that are recognized over time in line with service progress."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 79,
          "title": "Property and Equipment Breakdown",
          "data": [
            {
              "key": "Leasehold improvements",
              "value": "$44,418"
            },
            {
              "key": "Furniture and fixtures",
              "value": "$12,274"
            },
            {
              "key": "Computer hardware and office equipment",
              "value": "$32,843"
            },
            {
              "key": "Computer software",
              "value": "$44,151"
            },
            {
              "key": "Construction in progress",
              "value": "$8,984"
            },
            {
              "key": "Accumulated depreciation",
              "value": "-$131,930"
            },
            {
              "key": "Property and equipment, net",
              "value": "$102,499"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 79,
          "title": "Expense Breakdown and Depreciation Statement",
          "data": [
            {
              "key": "Cost of revenue",
              "value": "$15,406"
            },
            {
              "key": "General and administrative",
              "value": "$18,125"
            },
            {
              "key": "Research and development",
              "value": "$1,841"
            },
            {
              "key": "Total depreciation",
              "value": "$35,372"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 79,
          "title": "Operating Lease Liabilities Schedule",
          "data": [
            {
              "key": "Total remaining lease payments",
              "value": "$96,767"
            },
            {
              "key": "Less: imputed interest",
              "value": "-$21,231"
            },
            {
              "key": "Long-term operating lease liabilities",
              "value": "$68,952"
            },
            {
              "key": "Weighted-average remaining lease term (in years)",
              "value": "12.33"
            },
            {
              "key": "Weighted-average discount rate",
              "value": "3.7%"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 80,
          "title": "Lease Activity Summary",
          "data": [
            {
              "key": "Operating lease costs",
              "value": "13135"
            },
            {
              "key": "Right-of-use assets obtained in exchange for operating lease liabilities",
              "value": "9149"
            },
            {
              "key": "Cash paid for operating leases",
              "value": "11222"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 80,
          "title": "Goodwill Changes Summary",
          "data": [
            {
              "key": "Balance at December 31, 2021",
              "value": "527115"
            },
            {
              "key": "Adjustment",
              "value": "-4349"
            },
            {
              "key": "Balance at December 31, 2022",
              "value": "522766"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 89,
          "title": "Stock Options Valuation, Vesting, and Exercise Details",
          "data": [
            {
              "key": "Company",
              "value": "NEOGENOMICS, INC."
            },
            {
              "key": "Valuation Parameters",
              "value": "For the 2020 grant date, a trinomial lattice model was used to estimate option values. Metrics include Expected Term (ranges: 3.0–5.5, 1.2–5.5, 3.8–5.5 years), Risk-free Interest Rate (ranges: 1.4%-4.5%, 0.2%-1.3%, 0.2%-1.7%), Expected Volatility (ranges: 41.9%-66.7%, 38.7%-51.4%, 39.9%-44.6%), and Weighted Average Fair Value per Share ($6.42, $18.87, $8.88) across three periods. No dividend yield was reported."
            },
            {
              "key": "Stock Options Status (Historical)",
              "value": "Tables summarize stock option movements from 2019 to 2022 including statuses such as Outstanding, Granted, Exercised, and Forfeited with corresponding number of shares and average exercise prices. Notable fluctuations: Outstanding options decline from 5.3M (2019) to 3.8M (2020) to 3.0M (2021) and then increase to 4.2M (2022); exercise prices vary significantly across periods."
            },
            {
              "key": "Vesting Status",
              "value": "The vesting table for 2022 shows that non‐vested options increased from 1.29M at December 31, 2021 to 3.34M at December 31, 2022, with 4.49M options granted at an average fair value of $6.42, 684,633 vested, and 1.76M forfeited at an average fair value of $10.27."
            },
            {
              "key": "Exercise Prices and Option Details",
              "value": "Options are categorized by exercise price ranges from $7.34–$8.13 up to $21.41–$55.40. Total outstanding options amount to 4,214,617 with a weighted average exercise price of $16.48 and an average remaining life of 5.55 years. Out of these, 873,808 options are exercisable with a weighted average price of $27.53 and remaining life of 2.43 years."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 90,
          "title": "Executive Compensation: Stock Options and Restricted Stock Awards Analysis",
          "data": [
            {
              "key": "Aggregate intrinsic value of all stock options outstanding (in-the-money)",
              "value": "$1.4 million"
            },
            {
              "key": "Intrinsic value calculation closing price",
              "value": "$9.24"
            },
            {
              "key": "Total in-the-money options outstanding and exercisable as of Dec 31, 2022",
              "value": "0.1 million"
            },
            {
              "key": "Intrinsic value of options exercised in 2022",
              "value": "$6.1 million"
            },
            {
              "key": "Intrinsic value of options exercised in 2021",
              "value": "$46.7 million"
            },
            {
              "key": "Intrinsic value of options exercised in 2020",
              "value": "$68.6 million"
            },
            {
              "key": "Cash proceeds from exercise of stock options in 2022",
              "value": "$10.3 million"
            },
            {
              "key": "Cash proceeds from exercise of stock options in 2021",
              "value": "$13.7 million"
            },
            {
              "key": "Cash proceeds from exercise of stock options in 2020",
              "value": "$18.4 million"
            },
            {
              "key": "Total fair value of options granted in 2022",
              "value": "$28.9 million"
            },
            {
              "key": "Total fair value of options granted in 2021",
              "value": "$23.2 million"
            },
            {
              "key": "Total fair value of options granted in 2020",
              "value": "$7.5 million"
            },
            {
              "key": "Total fair value of option shares vested in 2022",
              "value": "$8.3 million"
            },
            {
              "key": "Total fair value of option shares vested in 2021",
              "value": "$11.7 million"
            },
            {
              "key": "Total fair value of option shares vested in 2020",
              "value": "$5.2 million"
            },
            {
              "key": "Stock-based compensation expense for stock options in 2022",
              "value": "$8.1 million"
            },
            {
              "key": "Stock-based compensation expense for stock options in 2021",
              "value": "$11.6 million"
            },
            {
              "key": "Stock-based compensation expense for stock options in 2020",
              "value": "$6.0 million"
            },
            {
              "key": "Unrecognized stock-based compensation cost for non-vested stock options as of Dec 31, 2022",
              "value": "$13.5 million over 2.1 years"
            },
            {
              "key": "Restricted Stock Awards - Nonvested shares at Dec 31, 2022",
              "value": "1,994,861 shares"
            },
            {
              "key": "Restricted Stock Awards - Weighted average grant date fair value at Dec 31, 2022",
              "value": "$12.71"
            },
            {
              "key": "Stock-based compensation expense for restricted stock in 2022",
              "value": "$15.5 million"
            },
            {
              "key": "Stock-based compensation expense for restricted stock in 2021",
              "value": "$9.8 million"
            },
            {
              "key": "Stock-based compensation expense for restricted stock in 2020",
              "value": "$3.4 million"
            },
            {
              "key": "Unrecognized stock-based compensation cost for non-vested restricted stock as of Dec 31, 2022",
              "value": "$17.1 million over 2.2 years"
            },
            {
              "key": "Summary of Restricted Stock Awards Movement (2019-2022)",
              "value": "Significant increase in granted shares in 2022 with lower fair value; large increase in forfeitures; nonvested shares increased from 335,298 in 2019 to 1,994,861 in 2022 with a decrease in weighted average grant date fair value from $15.75 to $12.71."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 91,
          "title": "Modifications of Stock Option and Restricted Stock Awards & Employee Stock Purchase Plan",
          "data": [
            {
              "key": "Accelerated Vesting of Stock Option Awards",
              "value": "353,265 awards accelerated"
            },
            {
              "key": "Accelerated Vesting of Restricted Stock Awards",
              "value": "285,114 awards accelerated"
            },
            {
              "key": "Incremental Stock-Based Compensation Recognized",
              "value": "$8.6 million"
            },
            {
              "key": "Stock Option Award Compensation Expense",
              "value": "$2.7 million"
            },
            {
              "key": "Restricted Stock Award Compensation Expense",
              "value": "$5.9 million"
            },
            {
              "key": "Employee Stock Purchase Plan Expense (2022)",
              "value": "$1.0 million"
            },
            {
              "key": "Employee Stock Purchase Plan Expense (2021)",
              "value": "$1.1 million"
            },
            {
              "key": "Employee Stock Purchase Plan Expense (2020)",
              "value": "$0.9 million"
            },
            {
              "key": "ESPP Shares Issued (2022)",
              "value": "415,450 shares"
            },
            {
              "key": "ESPP Shares Issued (2021)",
              "value": "112,094 shares"
            },
            {
              "key": "ESPP Shares Issued (2020)",
              "value": "138,309 shares"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 102,
          "title": "ITEM 11. EXECUTIVE COMPENSATION",
          "data": [
            {
              "key": "Description",
              "value": "The information required by this Item 11 will be included in the Definitive Proxy Statement referenced above in Item 10 and is incorporated herein by reference."
            },
            {
              "key": "Additional Reference",
              "value": "Definitive Proxy Statement relating to the 2023 Annual Meeting of Stockholders."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 108,
          "title": "Executive Compensation and Benefits Details",
          "data": [
            {
              "key": "Employment Location",
              "value": "Initially Bedford, Massachusetts; eventually Fort Meyers, Florida; subject to business travel"
            },
            {
              "key": "Base Salary",
              "value": "$525,000 per year, subject to periodic adjustment by the Board or Compensation Committee"
            },
            {
              "key": "Bonus Compensation",
              "value": "Annual bonus eligibility with a target bonus of 50% of Base Salary, based on performance and contingent on employment status at fiscal year end"
            },
            {
              "key": "Cash Sign-On Award",
              "value": "$350,000 to be paid within 30 days of Commencement Date, repayable if terminated for Cause or resignation without Good Reason within one year"
            },
            {
              "key": "Sign On Equity Awards",
              "value": "Equity grant (Initial Grant) with an aggregate target value of approximately $2,000,000, split between restricted stock and stock options, subject to Board/Compensation Committee approval"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 109,
          "title": "Executive Compensation and Benefits Agreement Details",
          "data": [
            {
              "key": "Sign-on Equity Vesting",
              "value": "The sign-on equity grants vest ratably on an annual basis over a period of four years from the date of the grant, contingent on the Executive remaining employed through each applicable vesting date."
            },
            {
              "key": "Relocation Bonus",
              "value": "A relocation bonus of $250,000 is payable within 30 days after the Executive provides relocation documentation upon moving to Southwest Florida. This bonus must be repaid if the Executive is terminated for Cause or resigns without Good Reason within one year of the Commencement Date."
            },
            {
              "key": "Annual Equity Awards",
              "value": "Starting in 2023, the Executive is eligible for annual equity-based awards with a target value of $1,000,000, subject to Board or Compensation Committee approval and performance criteria."
            },
            {
              "key": "Employee Benefit Plans",
              "value": "The Executive will participate in all available employee benefit plans, except when benefits overlap with those provided under this Agreement."
            },
            {
              "key": "Vacation Policy",
              "value": "The Executive is entitled to vacation and/or paid time off in accordance with the Company policies."
            },
            {
              "key": "Business Expenses and Allowances",
              "value": "The Company will reimburse reasonable business expenses (including travel and lodging for Fort Myers trips) and provide a mobile phone and home internet allowance of $250 per month, subject to applicable limits and substantiation."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 110,
          "title": "Executive Agreement – Confidentiality, Non-Solicitation, Non-Compete and Termination Provisions",
          "data": [
            {
              "key": "Compensation Consideration",
              "value": "The Executive acknowledges that the provision of employment and the compensation provided under the Agreement constitute full, adequate and sufficient consideration for all duties, obligations, and covenants, including those under the Restrictive Covenant Agreement."
            },
            {
              "key": "Confidentiality, Non-Solicitation and Non-Compete",
              "value": "The Executive agrees to the terms of the Confidentiality, Non-Solicitation and Non-Compete Agreement (Restrictive Covenant Agreement), which is attached as Addendum A and incorporated into the Agreement."
            },
            {
              "key": "Termination Provisions",
              "value": "The Agreement outlines termination conditions including termination for Cause (with detailed notice and a cure period for failures), termination without Cause by the Company, and termination for Good Reason initiated by the Executive."
            },
            {
              "key": "Cause Definition",
              "value": "Cause includes failure to perform duties, breaches of material provisions of the Agreement or Restrictive Covenant Agreement, misconduct injurious to the Company, felony-related issues, policy violations related to discrimination or harassment, substance abuse preventing performance, misappropriation or embezzlement, and willful misconduct or gross negligence."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 111,
          "title": "Executive Termination, Good Reason, and Final Compensation Provisions",
          "data": [
            {
              "key": "Good Reason Definition",
              "value": "Occurs if there is a material diminution in the Executive’s Base Salary, a material diminution in title, authority, duties or responsibilities, a change of more than 50 miles in the required geographic work location, or any breach by the Company of a material provision of the Agreement without the Executive’s written consent."
            },
            {
              "key": "Without Good Reason Termination",
              "value": "The Executive may terminate his or her employment without Good Reason at any time upon 60 days’ notice to the Company, which may waive any portion of the notice period."
            },
            {
              "key": "Disability and Death Provisions",
              "value": "Employment is automatically terminated upon the Executive’s death; if disabled (physically or psychologically) and unable to perform substantially all duties for 90 days within any 365 consecutive days, termination may be effected following a required medical examination."
            },
            {
              "key": "Final Compensation Clause",
              "value": "Upon termination (except for termination by the Company for Cause), the Executive is entitled to the Base Salary for the final payroll period, reimbursement of approved business expenses (submitted within 60 days), and, if applicable, the annual bonus at target (or higher if awarded) for the prior fiscal year, payable with active employees' bonuses."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 112,
          "title": "Compensation and Severance Provisions",
          "data": [
            {
              "key": "Final Compensation Timing",
              "value": "Final Compensation will be paid within 30 days following the termination date or a legally required shorter period."
            },
            {
              "key": "Severance Payment Structure (Non-Change in Control)",
              "value": "Includes payments of 1x Base Salary (Base Severance), 1x Target Bonus (Bonus Severance), COBRA premium coverage with administrative fee, and accelerated vesting of Time-Based Equity Awards for a period equivalent to 12 months post-termination."
            },
            {
              "key": "Severance Payment Structure (Change in Control Period)",
              "value": "For terminations during Change in Control Period, the severance includes 2x Base Salary (Enhanced Base Severance), Bonus Severance, Health Continuation Benefits, and full accelerated vesting of all unvested Time-Based Equity Awards with extended option exercisability."
            },
            {
              "key": "Change in Control Definition",
              "value": "A section outlining events constituting a Change in Control, affecting severance computations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 113,
          "title": "Severance Payment Conditions & Change in Control Triggers",
          "data": [
            {
              "key": "Change in Control Triggers",
              "value": "The Exchange Act and Rule 13d-3, merger or consolidation events, complete liquidation or asset sale, or changes in Board composition over a two-year period (with a two-thirds board approval) constitute change in control events."
            },
            {
              "key": "Compliance with Section 409A",
              "value": "The 'Change in Control' must meet the requirements of a 'change in control event' under Treas. Reg. § 1.409A-3(i)(5)."
            },
            {
              "key": "Severance Agreement Requirement",
              "value": "The Executive must sign and return a timely and effective Separation Agreement containing a general release of claims for any severance payment obligations to vest."
            },
            {
              "key": "Payment Timing - Salary Continuation",
              "value": "Base and Enhanced Base Severance are payable as salary continuation over a 12-month period, starting on the Company's next regular payday after 60 calendar days post termination, retroactive to the day after termination."
            },
            {
              "key": "Payment Timing - Bonus Severance",
              "value": "Bonus Severance is payable as a lump sum on the Company's next payday after the expiration of 60 calendar days from the termination date."
            },
            {
              "key": "Health Continuation Payments and Equity Vesting",
              "value": "Health Continuation Payments are made monthly starting after the 60-day period, and accelerated vesting of Time-Based Equity Awards becomes effective as of the effective date of the Separation Agreement."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 114,
          "title": "Termination Provisions and Deferred Compensation under Section 409A",
          "data": [
            {
              "key": "Employee Benefits Termination",
              "value": "Termination of group health and dental plans at cost, and cessation of eligibility for vacation or paid time off upon employment termination."
            },
            {
              "key": "Survival of Provisions",
              "value": "Certain provisions survive termination, including obligations under the Restrictive Covenant Agreement."
            },
            {
              "key": "Deferred Compensation Timing",
              "value": "Payments that would normally be payable within six months post-termination are deferred until the next business day following the six-month period or upon the Executive’s death, in compliance with Section 409A."
            },
            {
              "key": "Specified Employee Definition",
              "value": "An individual determined by the Company to be a specified employee under Treasury regulation Section 1.409A-1(i) whose payments may be deferred accordingly."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 115,
          "title": "Executive Agreement - Representations, Compliance, and Payment Provisions",
          "data": [
            {
              "key": "Section 409A Liability",
              "value": "The Company and its Affiliates are not liable for any failure of payment or benefits under the Agreement to comply with or be exempt from Section 409A requirements."
            },
            {
              "key": "Executive Representations",
              "value": "The Executive warrants that nothing in his/her past legal, work, or personal experiences would impair his/her ability to serve as President, Clinical Services, confirms no criminal health care-related offense, and verifies no existing restrictions that could prevent executing the Agreement."
            },
            {
              "key": "Compliance Agreements",
              "value": "The Executive agrees to comply with all federal and state laws and regulations, as well as compliance guidance (e.g., Medicare/Medicaid anti-kickback law, Stark self-referral prohibition, and guidelines from the Office of the Inspector General), and to immediately report any suspected compliance issues."
            },
            {
              "key": "Withholding",
              "value": "All payments under the Agreement will be reduced by any tax or other required withholdings as mandated by law."
            },
            {
              "key": "Section 280G",
              "value": "If any payment qualifies as a 'parachute payment' under Section 280G and would be subject to an excise tax under Section 4999, then such payment shall be reduced accordingly."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 116,
          "title": "Reduced Amount Calculation and Parachute Payment Adjustments",
          "data": [
            {
              "key": "Payment Reduction Calculation",
              "value": "Defines ‘Reduced Amount’ as either the maximum payment exempt from Excise Tax or the max amount after taxes ensuring greater after-tax receipt. It outlines calculation assumptions using federal, state, and local taxes computed at highest marginal rates."
            },
            {
              "key": "Reduction Order",
              "value": "Specifies reduction in order: first, cash payments; next, employee benefits; finally, cancellation of accelerated vesting of outstanding equity awards, with vesting adjustments done in reverse grant order."
            },
            {
              "key": "Determination Authority",
              "value": "Calculations and determinations to be made by an independent accounting/consulting firm or tax counsel whose rulings are binding on the Company and the Executive, relying on reasonable assumptions regarding Sections 280G and 4999."
            },
            {
              "key": "Assignment and Miscellaneous Provisions",
              "value": "Additional contractual provisions include restrictions on assignment, severability, and supremacy of this agreement over equity award agreements relating to termination treatments."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 120,
          "title": "Executive Compensation and Benefits Terms",
          "data": [
            {
              "key": "Base Salary",
              "value": "$525,000 per year"
            },
            {
              "key": "Bonus Target",
              "value": "50% of Base Salary; annual bonus eligibility based on performance"
            },
            {
              "key": "Sign On Equity Awards",
              "value": "Initial equity grant with aggregate target value of approximately $2,000,000; half as restricted stock and half as stock options vesting over four years"
            },
            {
              "key": "Annual Equity Awards",
              "value": "Additional equity-based awards beginning in 2023 with a target value of $1,000,000, subject to performance and board approval"
            },
            {
              "key": "Bonus Payment Deadline",
              "value": "Payment of earned bonus not later than March 15 of the following fiscal year"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 121,
          "title": "Executive Compensation and Benefits Provisions",
          "data": [
            {
              "key": "Board Approval",
              "value": "Compensation terms, including Annual Grants, are approved by the Board or the Compensation Committee."
            },
            {
              "key": "Annual Grants",
              "value": "Terms and conditions for Annual Grants are determined by the Board or the Compensation Committee."
            },
            {
              "key": "Employee Benefit Plans",
              "value": "Executive is entitled to participate in all employee benefit plans applicable to Company employees, subject to plan terms and non-duplication with other benefits."
            },
            {
              "key": "Vacations",
              "value": "Entitlement to vacation and/or paid time-off as per Company policies."
            },
            {
              "key": "Business Expenses",
              "value": "Reimbursement for reasonable business expenses (including travel and lodging for travel to Fort Myers while residing in Colorado) and a mobile phone plus home internet allowance of $250 per month. Reimbursements follow specific timing and substantiation rules."
            },
            {
              "key": "Expense Reimbursement Timing",
              "value": "Reimbursement is to be made by December 31 of the calendar year following the incurred expense."
            },
            {
              "key": "Confidentiality and Related Covenants",
              "value": "The Executive has agreed to and signed a Confidentiality, Non-Solicitation and Non-Compete Agreement (Addendum A), which is incorporated into the Agreement."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 122,
          "title": "Executive Termination Provisions",
          "data": [
            {
              "key": "Termination for Cause",
              "value": "Outlined conditions include failure to perform duties after notice and a 30-business day cure period, breach of material provision or restrictive covenant, willful misconduct injurious to the company, felony commission, policy violations (discrimination, harassment, workplace violence), illegal drug use or repeated alcohol abuse, misappropriation, embezzlement, or gross negligence."
            },
            {
              "key": "Company Termination Without Cause",
              "value": "The Company may terminate the Executive’s employment at any time other than for Cause upon written notice."
            },
            {
              "key": "Termination by Executive for Good Reason",
              "value": "Executive may terminate if there is a material diminution in Base Salary, title/authority/duties, significant geographic change (over 50 miles), or breach by the Company of a material provision. Notice must be given with detailed description and specific cure periods (60-day notice with a subsequent 30-day cure period)."
            },
            {
              "key": "Termination by Executive Without Good Reason",
              "value": "The Executive may terminate employment at any time upon 30 days’ notice, which the Company may waive partially or fully."
            },
            {
              "key": "Death and Disability",
              "value": "Employment automatically terminates upon death and may be terminated if the Executive becomes disabled or unable to perform substantially all duties."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 123,
          "title": "Final Compensation and Severance Provisions",
          "data": [
            {
              "key": "Final Compensation",
              "value": "Upon termination (except terminations for Cause), the Executive shall receive: (i) base salary for the final payroll period; (ii) reimbursement of business expenses (with substantiation within 60 days); and (iii) the annual bonus at target (or higher if awarded) for the previous fiscal year, paid concurrently with bonuses for active employees."
            },
            {
              "key": "Severance Payments",
              "value": "For terminations under specified sections (excluding those during the Change in Control Period), the severance includes: (i) Base Severance equal to one times the Base Salary; (ii) Bonus Severance equal to one times the Target Bonus; (iii) Health Continuation Benefits covering 100% of monthly COBRA premiums plus a 2% administration fee until the earliest of specified events; and (iv) additional provisions (text truncated)."
            },
            {
              "key": "Medical Examination Provision",
              "value": "The Executive must submit to a company-selected physician’s examination if questions arise regarding disability affecting performance of duties; refusal binds the Executive to the Company’s determination."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 124,
          "title": "Executive Severance and Change in Control Provisions",
          "data": [
            {
              "key": "Time-Based Equity Award",
              "value": "Equity-based awards vesting solely on continued employment; acceleration of vesting for the portion that would have vested in the 12-month period following termination."
            },
            {
              "key": "Option Exercise Period",
              "value": "Executive has twelve months from termination to exercise options."
            },
            {
              "key": "Severance Payment - Change in Control Period",
              "value": "For terminations during the Change in Control Period, executive receives Enhanced Base Severance (2x Base Salary), Bonus Severance, and Health Continuation Benefits."
            },
            {
              "key": "Acceleration of Equity Awards",
              "value": "Outstanding unvested Time-Based Equity Awards accelerate in full immediately prior to termination, or upon Change in Control if termination occurs in the three-month period preceding it."
            },
            {
              "key": "Share Options Exercisability",
              "value": "Outstanding options remain exercisable for one year following termination (or until the end of the option term)."
            },
            {
              "key": "Change in Control Definition",
              "value": "Defined as events including acquisition of voting stock exceeding 50%, merger/consolidation preserving at least 50% voting power, liquidation or sale of substantially all assets, or specific board changes with a two-thirds vote."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 125,
          "title": "Conditions To And Timing Of Severance Payments",
          "data": [
            {
              "key": "Change in Control Reference",
              "value": "Requires compliance with Section 409A and Treas. Reg. § 1.409A-3(i)(5) defining a 'change in control event'."
            },
            {
              "key": "Severance Agreement Requirement",
              "value": "Executive must sign and return a separation agreement within 60 calendar days post-termination to receive severance payments."
            },
            {
              "key": "Base Severance Payment",
              "value": "Salary continuation over a 12-month period following termination, with the first payment made on the next regular payday after 60 calendar days, retroactive to the day following termination."
            },
            {
              "key": "Bonus Severance Payment",
              "value": "Payable in a lump sum on the next regular payday after the 60-day period following termination."
            },
            {
              "key": "Health Continuation Payments",
              "value": "Made on a monthly basis starting after the expiration of 60 calendar days from termination."
            },
            {
              "key": "Accelerated Vesting of Time-Based Equity Awards",
              "value": "Becomes effective as of the date the Separation Agreement is executed."
            },
            {
              "key": "Benefits Termination",
              "value": "Executive’s participation in employee benefit plans terminates per plan terms upon employment termination, excluding rights under COBRA or similar laws."
            },
            {
              "key": "Survival Clause",
              "value": "Certain provisions, including obligations under the Separation and Restrictive Covenant Agreements, survive termination."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 126,
          "title": "Timing of Payments and Section 409A; Executive Representations",
          "data": [
            {
              "key": "Deferred Payment Terms",
              "value": "If at the time of termination the Executive is a 'specified employee,' any amounts payable within six months following termination will be deferred and paid on the next business day after the six-month period expires, or earlier upon the Executive’s death, subject to certain exceptions."
            },
            {
              "key": "Section 409A Compliance",
              "value": "Payments under this Agreement are structured to comply with Treasury regulation Section 1.409A and may include exceptions, such as amounts not constituting deferrals of compensation, excepted welfare benefits, or other non-Section 409A amounts. The Agreement also clarifies that 'termination of employment' is treated as a 'separation from service' for compliance."
            },
            {
              "key": "Separate Payment Structure",
              "value": "Each payment is treated as a separate installment, meaning the right to a series of installment payments is the right to a series of separate payments, with no company liability for non-compliance with Section 409A."
            },
            {
              "key": "Executive Representations",
              "value": "The Executive represents that no past legal, work, or personal experiences will impair his ability to serve as President, Enterprise Operations, confirms no criminal or disqualifying healthcare-related issues, asserts no legal restraints that prevent execution of the Agreement, and guarantees not to use confidential information from previous employers."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 127,
          "title": "Compliance, Withholding, and Section 280G Provisions in Executive Agreement",
          "data": [
            {
              "key": "Compliance Obligations",
              "value": "The Executive must provide services in compliance with applicable federal and state laws and regulations, including specific compliance guidance (e.g., Medicare and Medicaid anti-kickback law, Stark self-referral prohibition, etc.) and remain educated on these requirements."
            },
            {
              "key": "Withholding",
              "value": "All payments under the agreement will be reduced by required tax or other amounts withheld as mandated by applicable law."
            },
            {
              "key": "Section 280G Compliance",
              "value": "If any payment constitutes a 'parachute payment' under Section 280G of the IRC, it will be reduced to a 'Reduced Amount' to avoid or lessen excise tax under Section 4999. The reduction process prioritizes cash payments, followed by employee benefits and adjustments in accelerated vesting of equity awards, with determinations made by independent Tax Counsel."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 131,
          "title": "Separation Agreement with William Bonello",
          "data": [
            {
              "key": "Separation Date",
              "value": "December 31, 2022"
            },
            {
              "key": "Position",
              "value": "Chief Financial Officer"
            },
            {
              "key": "Base Salary",
              "value": "$455,000"
            },
            {
              "key": "Severance Period",
              "value": "12 months"
            },
            {
              "key": "Severance Payments",
              "value": "Base salary for 12 months following Separation Date"
            },
            {
              "key": "Bonus Severance",
              "value": "$227,500"
            },
            {
              "key": "Payment Terms",
              "value": "Payments made in accordance with the Company's payroll practices, first payment after 60 days from Separation Date."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 132,
          "title": "Separation Benefits and Executive Compensation",
          "data": [
            {
              "key": "Health Continuation Benefits",
              "value": "Monthly payment equal to 100% of monthly COBRA premiums plus 2% administration fee until end of Severance Period."
            },
            {
              "key": "Time-Based Equity Award",
              "value": "Each award that would have vested in next 12 months becomes vested as of Separation Date."
            },
            {
              "key": "Restricted Stock",
              "value": "34,294 of 82,305 shares vest as of Separation Date, rest automatically terminate."
            },
            {
              "key": "Retention Bonus",
              "value": "Remaining portion of retention bonus ($100,000) vests as of Separation Date."
            },
            {
              "key": "Non-competition Restriction",
              "value": "Limited to one-year period following Separation Date."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 136,
          "title": "Payment and Reimbursement Under Agreement",
          "data": [
            {
              "key": "Payment Rules",
              "value": "The right to payment or reimbursement is subject to specified rules regarding the timing and nature of payments."
            },
            {
              "key": "Specified Employee Definition",
              "value": "Includes provisions for payments upon termination affecting the timing of payments based on IRS regulations."
            },
            {
              "key": "Governing Law",
              "value": "This Agreement is governed by the laws of the State of Florida."
            },
            {
              "key": "Arbitration Clause",
              "value": "Any disputes will be settled through arbitration under American Arbitration Association rules."
            },
            {
              "key": "Counterparts Provision",
              "value": "Agreement can be executed in counterparts and transmitted by facsimile."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 140,
          "title": "CERTIFICATIONS",
          "data": [
            {
              "key": "Officer Name",
              "value": "Christopher M. Smith"
            },
            {
              "key": "Title",
              "value": "Director and Chief Executive Officer"
            },
            {
              "key": "Report Date",
              "value": "February 24, 2023"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_rnd_investment_numbers": {
      "value": true,
      "elements": [
        {
          "type": "rnd_investment",
          "page": 6,
          "title": "Table of Contents",
          "data": [
            {
              "key": "Company",
              "value": "NEOGENOMICS, INC."
            },
            {
              "key": "Service Overview",
              "value": "Provides comprehensive testing services supporting pharmaceutical oncology programs, from discovery to commercialization."
            },
            {
              "key": "Biomarker Discovery",
              "value": "Helps customers develop biomarker hypotheses by recommending optimal platforms for molecular screening and providing robust informatics support."
            },
            {
              "key": "Companion Diagnostic Development",
              "value": "Develops tests to be used as companion diagnostics to determine patients’ responses to specific drugs, with readiness for immediate market launch post-FDA approval."
            },
            {
              "key": "Clinical Trials Support",
              "value": "Offers extensive support in clinical trials including rapid turnaround, dedicated project management, quality assurance oversight, and key analysis and insights."
            },
            {
              "key": "Market Segments",
              "value": "Operates primarily in Genetic and Molecular testing while also providing Anatomic Pathology testing; serves segments including Clinical Pathology, Anatomic Pathology, and Genetic & Molecular testing."
            },
            {
              "key": "Data and Informatics",
              "value": "Invests in leading technologies to ensure data security, enhance informatics capabilities, and provide clinical decision support tools."
            },
            {
              "key": "Regulatory Experience",
              "value": "Experienced in supporting FDA submissions for companion diagnostics."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 48,
          "title": "Research and Development Expenses",
          "data": [
            {
              "key": "Category",
              "value": "Research and development"
            },
            {
              "key": "Total Amount (in thousands)",
              "value": "30326"
            },
            {
              "key": "Base Amount (in thousands)",
              "value": "21873"
            },
            {
              "key": "Difference (in thousands)",
              "value": "8453"
            },
            {
              "key": "Percentage Change",
              "value": "38.6%"
            },
            {
              "key": "Additional Note",
              "value": "Expenses increased $8.5 million in 2022 primarily due to higher R&D costs for the Inivata subsidiary acquired in June 2021. The company expects further significant increases as it invests in strategic innovation projects and bringing new tests to market."
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_new_product_launches": {
      "value": true,
      "elements": [
        {
          "type": "product_launch",
          "page": 7,
          "title": "Focus Areas & New Product Initiatives",
          "data": [
            {
              "key": "Company",
              "value": "NEOGENOMICS, INC."
            },
            {
              "key": "Overview",
              "value": "The document highlights precision medicine and genetic/molecular testing in cancer care with emphasis on its market growth factors."
            },
            {
              "key": "Market Influencers",
              "value": "Increased gene discovery, rising cancer incidence in the elderly, targeted drugs necessitating companion diagnostics, enhanced patient/payer awareness, reduced testing costs, improved third-party payer coverage, and expanded health insurance coverage."
            },
            {
              "key": "2023 Focus Areas",
              "value": "Sustain a purpose-driven culture, maintain excellence in service and performance, and grow through innovation, while transforming cancer care."
            },
            {
              "key": "Profitably Grow Core Business",
              "value": "Increase testing volume and NGS mix; improve turnaround time; win on service; optimize commercial operations; and improve product offerings."
            },
            {
              "key": "Accelerate Advanced Diagnostics",
              "value": "Execute clinical RaDaR™ (MRD) launch and launch Neo Comprehensive, a new NGS offering; continue to drive pharma growth and enhance enterprise data strategies."
            },
            {
              "key": "Improve Profitability",
              "value": "Boost productivity and efficiency; control general and administrative spending; invest in focused initiatives; and prioritize revenue cycle management."
            },
            {
              "key": "Competitive Strengths",
              "value": "Superior testing technologies, advanced instrumentation, robust laboratory information systems, effective client education programs, and a broad domestic and international presence."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 19,
          "title": "Product Development Challenges",
          "data": [
            {
              "key": "Overview",
              "value": "New product development and commercialization involve a lengthy and complex process."
            },
            {
              "key": "Risks",
              "value": "High degree of risk in product development, including potential failure to meet expected performance."
            },
            {
              "key": "Investment Needs",
              "value": "Significant investments in research, development, and clinical studies are required."
            },
            {
              "key": "Market Challenges",
              "value": "Competitors may introduce new technologies that could decrease demand for current services."
            },
            {
              "key": "Contractual Risks",
              "value": "Termination or reduction in scope of contracts with Pharma Services clients could affect revenues."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 41,
          "title": "Table of Contents – NEOGENOMICS, INC. Product Strategy and Regulatory Environment",
          "data": [
            {
              "key": "Product Launch",
              "value": "Launch Neo Comprehensive, new NGS offering"
            },
            {
              "key": "Strategic Initiatives",
              "value": "Continue to improve Pharma growth and profitability; Focus on enterprise data strategy; Improve productivity and efficiency; Manage general and administrative spend; Prioritize revenue cycle management; Structured departmental goals and employee incentive plans."
            },
            {
              "key": "Regulatory Environment",
              "value": "FDA considering increased oversight of LDTs, including proposed frameworks and the VALID Act; shifting policy landscape amid COVID-19-related announcements."
            },
            {
              "key": "Reportable Segments",
              "value": "Clinical Services Segment and Pharma Services Segment, with detailed financial information relevant to revenues, cost of revenue, and gross margin."
            },
            {
              "key": "Clinical Services",
              "value": "Non-competitive partner model with community-based pathology practices, hospital labs, and academic centers; Offers technical (TC) and professional (PC) components; Leading provider of Molecular and NGS testing."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_capital_expenditures": {
      "value": true,
      "elements": [
        {
          "type": "capital_expenditure",
          "page": 52,
          "title": "Contractual Obligations and Capital Expenditures Summary",
          "data": [
            {
              "key": "Table Title",
              "value": "Contractual Obligations Summary"
            },
            {
              "key": "Equipment financing obligations (Total)",
              "value": "70 (in thousands)"
            },
            {
              "key": "Operating lease obligations (Total)",
              "value": "96,767 (in thousands)"
            },
            {
              "key": "Principal payments of long-term debt (Total)",
              "value": "535,322 (in thousands)"
            },
            {
              "key": "Total contractual obligations",
              "value": "633,164 (in thousands)"
            },
            {
              "key": "Capital Expenditures 2022",
              "value": "$30.9 million"
            },
            {
              "key": "Capital Expenditures 2023 Forecast Range",
              "value": "$30.0 million to $40.0 million"
            },
            {
              "key": "Additional Commentary",
              "value": "Significant long-term commitments with over 62% obligations beyond 5 years; convertible notes details and interest rate risk disclosure also provided."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_expenditure",
          "page": 67,
          "title": "Table of Contents - Accounting Policies",
          "data": [
            {
              "key": "Prepaid Expense",
              "value": "Costs paid but not yet incurred. Amounts expected to be incurred within one year are recorded as prepaid assets (current assets), while those expected beyond one year are recorded as other assets (non-current assets) on the Consolidated Balance Sheets."
            },
            {
              "key": "Assets Held For Sale",
              "value": "Assets to be disposed of by sale are reclassified as held for sale if their carrying amounts are expected to be recovered primarily through a sale transaction rather than continuing use. Held-for-sale assets are measured at the lower of carrying value or fair value less selling costs and are presented as current assets when the sale is reasonably certain within one year."
            },
            {
              "key": "Other Current Assets",
              "value": "As of December 31, 2022 and 2021, these mainly consist of receivables related to R&D tax credits, pharma contract assets, and other non-trade receivables."
            },
            {
              "key": "Property and Equipment, net",
              "value": "Property and equipment are recorded at cost, net of accumulated depreciation and amortization. Depreciation, amortization, and capitalization policies (including for internal-use software) are applied on a straight-line basis over the estimated useful lives. Changes in estimates are recorded prospectively."
            },
            {
              "key": "Leases",
              "value": "The Company leases corporate offices and laboratory spaces under operating leases, with lease liabilities recorded based on the present value of future lease payments. Lease terms, renewals, incentives, and non-lease components are considered in the classification and measurement of these liabilities."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_financial_performance_indicators": {
      "value": true,
      "elements": [
        {
          "type": "financial_performance",
          "page": 1,
          "title": "UNITED STATES SECURITIES AND EXCHANGE COMMISSION - FORM 10-K",
          "data": [
            {
              "key": "Registrant",
              "value": "NEOGENOMICS, INC."
            },
            {
              "key": "Fiscal Year End",
              "value": "December 31, 2022"
            },
            {
              "key": "Commission File Number",
              "value": "001-35756"
            },
            {
              "key": "Incorporation Jurisdiction",
              "value": "Nevada"
            },
            {
              "key": "IRS Employer Identification No.",
              "value": "74-2897368"
            },
            {
              "key": "Address",
              "value": "9490 NeoGenomics Way, Fort Myers, FL 33912"
            },
            {
              "key": "Phone",
              "value": "(239) 768-0600"
            },
            {
              "key": "Securities Registered (Section 12)",
              "value": "Common Stock, par value $0.001 per share (registered under Section 12(b) and 12(g))"
            },
            {
              "key": "Well-Known Seasoned Issuer",
              "value": "Yes"
            },
            {
              "key": "Filing Status (Reports required under Section 13 or 15(d))",
              "value": "Yes filed; subject to all filing requirements"
            },
            {
              "key": "Electronic Data Files Submitted",
              "value": "Yes"
            },
            {
              "key": "Large Accelerated Filer",
              "value": "Yes"
            },
            {
              "key": "Internal Control over Financial Reporting Attestation",
              "value": "Yes"
            },
            {
              "key": "Shell Company",
              "value": "No"
            },
            {
              "key": "Aggregate Market Value (Non-affiliate holdings as of June 30, 2022)",
              "value": "$755 million based on a closing price of $8.15 per share"
            },
            {
              "key": "Outstanding Shares (as of February 20, 2023)",
              "value": "127,457,980"
            },
            {
              "key": "Incorporated By Reference",
              "value": "Portions of the Proxy Statement for the 2023 Annual Meeting of Stockholders are incorporated by reference into Part III"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 4,
          "title": "Table of Contents / Business Overview",
          "data": [
            {
              "key": "Company Name",
              "value": "NeoGenomics, Inc."
            },
            {
              "key": "Ticker",
              "value": "NEO"
            },
            {
              "key": "Business Description",
              "value": "The document outlines the Company’s business model and operations as described in Part I, Item 1. Business. NeoGenomics provides a wide range of oncology diagnostic testing and consultative services through a network of laboratories across the United States, Europe, and Asia."
            },
            {
              "key": "Laboratory Accreditations",
              "value": "CAP accredited and CLIA certified laboratories in several U.S. locations; additional labs in Rolle (Switzerland), Singapore, and China; pending CAP accreditation in Cambridge, United Kingdom."
            },
            {
              "key": "Testing Services Offered",
              "value": "Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Immunohistochemistry (IHC) & Digital Imaging, Molecular testing, and Morphologic analysis."
            },
            {
              "key": "Mission & Vision",
              "value": "Mission is to save lives by improving patient care; vision is to become the world’s leading cancer testing, information, and decision support company."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 5,
          "title": "Table of Contents – NEOGENOMICS, INC.",
          "data": [
            {
              "key": "Primary Diagnosis & Secondary Consultations",
              "value": "Mentions sample processing, initial diagnosis, and secondary consultations for complex cases."
            },
            {
              "key": "Customer Segments",
              "value": "Clinical (community-based pathology, oncology practices, hospital labs, reference labs, academic centers) and Pharma (pharmaceutical companies supporting research studies and clinical trials)."
            },
            {
              "key": "Revenue Breakdown",
              "value": "Clinical Services account for 82% of consolidated revenue; Pharma Services account for 18%."
            },
            {
              "key": "Service Details",
              "value": "Includes technical component (TC) and professional component (PC) testing services; molecular and NGS testing capabilities detailed with targeted panels complemented by IHC and FISH tests."
            },
            {
              "key": "Acquisition Highlight",
              "value": "The acquisition of Inivata enhanced oncology Liquid Biopsy technology capabilities (InVisionFirst-Lung and RaDaR assays)."
            },
            {
              "key": "Future Growth Driver",
              "value": "Molecular laboratory and NGS capabilities are expected to drive future growth."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 8,
          "title": "Table of Contents – NEOGENOMICS, INC.",
          "data": [
            {
              "key": "Turnaround Times",
              "value": "Emphasis on improving turnaround times in the Clinical Services segment to ensure rapid delivery of test results, driving additional testing requests and informing treatment decisions."
            },
            {
              "key": "Innovative Service Offerings",
              "value": "Detailed description of extensive tech-only FISH services along with advanced tech-only flow cytometry and IHC testing. Options between technical-only or global comprehensive testing including a physician’s interpretation are provided."
            },
            {
              "key": "Test Menus",
              "value": "Offers a range of molecular and NGS tests including single gene tests, targeted NeoTYPE panels, large NGS panels, and in Pharma Services, whole exome and whole genome sequencing."
            },
            {
              "key": "National Direct Sales Force",
              "value": "Sales operations organized into nine regions with dedicated teams using CRM and Laboratory Information Systems for real-time customer care and consultative selling."
            },
            {
              "key": "Seasonality and External Factors",
              "value": "Discussion of seasonality effects – declines in testing volume during vacation periods, holidays, and extreme weather conditions impacting revenues and cash flows; mentions specific risks related to patient enrollments in sponsored trials."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 10,
          "title": "NEOGENOMICS, INC. Payer Mix",
          "data": [
            {
              "key": "Client direct billing (2022)",
              "value": "67%"
            },
            {
              "key": "Client direct billing (2021)",
              "value": "63%"
            },
            {
              "key": "Client direct billing (2020)",
              "value": "63%"
            },
            {
              "key": "Commercial insurance (2022)",
              "value": "17%"
            },
            {
              "key": "Commercial insurance (2021)",
              "value": "19%"
            },
            {
              "key": "Commercial insurance (2020)",
              "value": "20%"
            },
            {
              "key": "Medicare and other government (2022)",
              "value": "16%"
            },
            {
              "key": "Medicare and other government (2021)",
              "value": "18%"
            },
            {
              "key": "Medicare and other government (2020)",
              "value": "17%"
            },
            {
              "key": "Total (all periods)",
              "value": "100%"
            },
            {
              "key": "Summary",
              "value": "The table reflects the breakdown of net clinical revenue by payer type over three years. Client direct billing shows a decline from 67% to 63%, Commercial insurance has increased slightly, while Medicare and other government funding remains relatively stable."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 23,
          "title": "Indebtedness and Convertible Notes Overview",
          "data": [
            {
              "key": "Convertible Notes Issued",
              "value": "$201.3 million aggregate principal amount of 2025 Convertible Notes"
            },
            {
              "key": "Convertible Notes Issued (2028)",
              "value": "$345.0 million aggregate principal amount of 2028 Convertible Notes"
            },
            {
              "key": "Future Indebtedness",
              "value": "Potential additional indebtedness may be incurred."
            },
            {
              "key": "Repayment Capability",
              "value": "Depends on future performance and economic factors."
            },
            {
              "key": "Cash Flow Generation",
              "value": "May not continue to generate sufficient cash flow to service indebtedness."
            },
            {
              "key": "Actions if Cash Flow Insufficient",
              "value": "May need to sell assets, restructure debt, or obtain equity capital."
            },
            {
              "key": "Capital Market Dependency",
              "value": "Refinancing ability depends on financial condition and capital markets."
            },
            {
              "key": "Default Risk Factors",
              "value": "Failure to repurchase Convertible Notes on time may lead to defaults."
            },
            {
              "key": "Capped Call Transactions Impact",
              "value": "Transactions may affect the value of the 2028 Convertible Notes and common stock."
            },
            {
              "key": "Dilution Risk",
              "value": "Conversion of Convertible Notes may dilute stockholder ownership."
            },
            {
              "key": "Short Selling Encouragement",
              "value": "Existence of Convertible Notes may promote short selling."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 39,
          "title": "Financial Performance - Cumulative Total Return Comparison & MD&A Overview",
          "data": [
            {
              "key": "Description",
              "value": "Comparison of cumulative total return to stockholders investing $100 from December 31, 2017 to December 31, 2022. The performance is compared against the S&P 500 Index, the Nasdaq Biotechnology Index (^NBI) and a customized peer group."
            },
            {
              "key": "Investment Details",
              "value": "Assumes reinvestment of all dividends with a starting investment of $100 tracking through December 31, 2022."
            },
            {
              "key": "Comparison Groups",
              "value": "NeoGenomics, Peer Group (Invitae Corporation, Exact Sciences Corporation, Laboratory Corporation of America Holdings, Natera, Inc., Quest Diagnostics, Inc.), S&P 500, and ^NBI."
            },
            {
              "key": "Chart Title",
              "value": "Five Year Cumulative Total Return to Our Stockholders of $100"
            },
            {
              "key": "Chart Metadata",
              "value": "Line chart with y-axis labeled 'Dollar Value' ranging from $0 to $750 and x-axis representing the years 2017 through 2022."
            },
            {
              "key": "Forward Looking Statement Disclaimer",
              "value": "The historical performance data is not indicative of future performance. The graph is not incorporated by reference into any filings under the Securities Act or the Exchange Act unless specifically stated."
            },
            {
              "key": "Additional Context",
              "value": "Part of the Annual Report on Form 10-K. Management’s Discussion and Analysis follows later in the document."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 44,
          "title": "Goodwill Impairment Test, Contingencies, Stock-Based Compensation & Revenue Recognition",
          "data": [
            {
              "key": "Goodwill Impairment Test",
              "value": "The document explains that a quantitative impairment test is performed by comparing the fair value of reporting units to their carrying values. Despite indicators such as changes in executive leadership and a drop in stock price (from $12.15 to $8.15 per share), the fair values exceeded carrying values as of June 30, 2022, so no impairment was recognized."
            },
            {
              "key": "Contingencies",
              "value": "It describes the process for accruing contingent losses based on management judgment and available information when losses can be reasonably estimated."
            },
            {
              "key": "Stock-Based Compensation",
              "value": "The company recognizes costs for share-based payment awards using methods such as the Black-Scholes option valuation model for awards granted from 2021 onward, with compensation recognized on a straight-line basis over the requisite service period."
            },
            {
              "key": "Revenue Recognition",
              "value": "Revenue for clinical diagnostic services is recognized upon performance and delivery of results. The recognition considers factors such as implicit price concessions, payer types (commercial insurance, Medicare, etc.), and estimated collection periods."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 45,
          "title": "Billing Source Distribution and Pharma Services Revenue",
          "data": [
            {
              "key": "table_title",
              "value": "Billing Source Distribution"
            },
            {
              "key": "table_summary",
              "value": "The table shows the distribution of billing sources across three time periods: Direct billing accounts for 63%-67%, Commercial insurance 17%-20%, and Medicare/other government sources 16%-18%. A slight decrease in direct billing over time is observed with a small increase in commercial insurance share."
            },
            {
              "key": "ent_direct_billing",
              "value": "67%, 63%, 63%"
            },
            {
              "key": "commercial_insurance",
              "value": "17%, 19%, 20%"
            },
            {
              "key": "medicare_and_government",
              "value": "16%, 18%, 17%"
            },
            {
              "key": "total_billing",
              "value": "100%, 100%, 100%"
            },
            {
              "key": "pharma_services_revenue_description",
              "value": "Describes the Pharma Services segment that contracts with pharmaceutical, biotech, and CRO customers. Revenue is recognized on a unit-of-service basis, with some contracts including upfront fees and deferred revenue recognition. It also covers contract assets, sales commissions, and deferred tax considerations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 46,
          "title": "Results of Operations and Net Revenue Analysis",
          "data": [
            {
              "key": "Overview",
              "value": "The document presents comparative income statement data for the years ended December 31, 2022 and 2021, shown as percentages of revenue. It includes key metrics such as cost of revenue, gross profit, operating expenses, and net loss."
            },
            {
              "key": "Income Statement Percentages",
              "value": "Total operating expenses were 67.8% in 2022 vs 63.1% in 2021, with loss from operations at -30.9% (2022) vs -24.5% (2021), and net loss at -28.3% (2022) vs -1.7% (2021). A notable change was the gain on investment in the second period affecting net loss figures."
            },
            {
              "key": "Net Revenue Breakdown",
              "value": "Clinical Services increased 3.6% from $404.2M to $418.8M, while Pharma Services increased 13.5% from $80.2M to $91.0M, resulting in an overall net revenue increase of 5.2% from $484.3M to $509.7M."
            },
            {
              "key": "Cost of Revenue Details",
              "value": "Cost of revenue for 2022 included $19.4M of amortization of acquired Inivata developed technology intangible assets, compared to 2021 which included $10.4M of amortization plus $5.3M write-offs related to COVID-19 PCR testing inventory."
            },
            {
              "key": "Segment Commentary",
              "value": "The Clinical Services segment benefited from increased average unit prices and a more favorable test mix, following the exit from COVID-19 PCR testing in 2021. Pharma Services growth was driven by increased volume and higher billings across its portfolio, including RaDaR™ testing."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 47,
          "title": "NEOGENOMICS, INC. Financial Performance",
          "data": [
            {
              "key": "Cost of Revenue",
              "value": "Total cost of revenue increased by 8.3% from $297,269K to $321,832K. Clinical Services, which include significant amortization of acquired Inivata developed technology intangibles ($17.1M in 2022 vs $9.2M in 2021) and, in 2021, a $5.3M write-off for COVID-19 PCR testing inventory, was the major contributor. Pharma Services cost of revenue also increased, reflecting higher amortization expenses ($2.4M in 2022 vs $1.2M in 2021)."
            },
            {
              "key": "Gross Profit",
              "value": "Gross profit showed a modest increase of 0.4%, rising from $187,060K to $187,896K. However, segment details reveal a decline in Clinical Services (-1.8%) and growth in Pharma Services (+13.3%). The overall gross profit margin declined from 38.6% in 2021 to 36.9% in 2022, mainly due to the impact of amortization and increased payroll-related costs."
            },
            {
              "key": "General and Administrative Expenses",
              "value": "General and administrative expenses increased by $22.0 million (9.9%), from $221,347K to $243,356K. This rise was influenced by additional expenses from the Inivata and Trapelo Health acquisitions, higher payroll and related costs, increased investments in technology, severance costs linked to executive departures, and stock-based compensation changes, partially offset by decreases in regulatory loss contingencies and acquisition-related costs."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 49,
          "title": "NEOGENOMICS, INC. Financial Performance Details",
          "data": [
            {
              "key": "Interest Expense",
              "value": "Interest expense, net decreased $3.6 million in 2022 compared to 2021. Reflects effective interest rates of 0.70% on 2028 Convertible Notes and 1.96% on 2025 Convertible Notes, with accrual starting at issuance and semi-annual payments. Also includes amortization related to fixed income investments offset by interest income on cash equivalents and marketable securities."
            },
            {
              "key": "Gain on Investment and Loan Receivable",
              "value": "Recorded a net gain on investment in and loan receivable from a non-consolidated affiliate of $109.3 million in 2021, with no corresponding gain in 2022. The table indicates a loss of $(109,260) offset by a gain of $109,260 and uses 'NM' to denote a not meaningful change."
            },
            {
              "key": "Net Loss",
              "value": "Net loss reported as $(144,250) in 2022 compared to $(8,347) in 2021, with detailed computations for basic and diluted net loss per share."
            },
            {
              "key": "Weighted Average Shares Outstanding",
              "value": "Basic and diluted weighted average shares outstanding were 124,217 in 2022 versus 119,962 in 2021."
            },
            {
              "key": "Net Loss per Share",
              "value": "Both basic and diluted net loss per share increased to (1.16) in 2022 from (0.07) in 2021."
            },
            {
              "key": "Non-GAAP Financial Measures",
              "value": "The report discusses the use of non-GAAP financial measures to provide transparency regarding operating performance, excluding certain non-core income and expense items."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 50,
          "title": "Non-GAAP Adjusted EBITDA Reconciliation and Cash Flow Summary",
          "data": [
            {
              "key": "Company",
              "value": "NeoGenomics, Inc."
            },
            {
              "key": "Definition",
              "value": "Non-GAAP Adjusted EBITDA defined as net loss from continuing operations adjusted for items including interest expense, taxes, depreciation, amortization, non-cash stock-based compensation, acquisition related expenses, COVID-19 inventory write-offs, CEO transition costs, headquarters moving expenses, gain on investments, loss contingency for regulatory matters, restructuring charges, and other significant/non-operating items."
            },
            {
              "key": "GAAP Net Loss (Current Period)",
              "value": "-144250 (in thousands)"
            },
            {
              "key": "GAAP Net Loss (Prior Period)",
              "value": "-8347 (in thousands)"
            },
            {
              "key": "Non-GAAP Adjusted EBITDA (Current Period)",
              "value": "-48010 (in thousands)"
            },
            {
              "key": "Non-GAAP Adjusted EBITDA (Prior Period)",
              "value": "-4161 (in thousands)"
            },
            {
              "key": "Key Adjustments",
              "value": "Depreciation, amortization, non-cash stock-based compensation, acquisition/integration expenses, CEO transition, restructuring charges, and other non-recurring items"
            },
            {
              "key": "Cash Flow and Liquidity",
              "value": "Operations primarily financed through operating cash flows, public and private debt and equity sales, and bank borrowings"
            },
            {
              "key": "Summary Insight",
              "value": "Significant increase in GAAP net loss and wider gap in Adjusted EBITDA from the prior period, driven by increased non-recurring expenses and higher depreciation/amortization."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 51,
          "title": "Net cash (used in) provided by",
          "data": [
            {
              "key": "Operating activities 2022",
              "value": "-65993"
            },
            {
              "key": "Operating activities 2021",
              "value": "-26723"
            },
            {
              "key": "Investing activities 2022",
              "value": "517"
            },
            {
              "key": "Investing activities 2021",
              "value": "-632367"
            },
            {
              "key": "Financing activities 2022",
              "value": "11829"
            },
            {
              "key": "Financing activities 2021",
              "value": "725285"
            },
            {
              "key": "Net change in cash and cash equivalents 2022",
              "value": "-53647"
            },
            {
              "key": "Net change in cash and cash equivalents 2021",
              "value": "66195"
            },
            {
              "key": "Cash, cash equivalents and restricted cash, beginning of year 2022",
              "value": "316827"
            },
            {
              "key": "Cash, cash equivalents and restricted cash, beginning of year 2021",
              "value": "250632"
            },
            {
              "key": "Cash and cash equivalents, end of year 2022",
              "value": "263180"
            },
            {
              "key": "Cash and cash equivalents, end of year 2021",
              "value": "316827"
            },
            {
              "key": "Working Capital, end of period 2022",
              "value": "515359"
            },
            {
              "key": "Working Capital, end of period 2021",
              "value": "594276"
            },
            {
              "key": "Summary",
              "value": "This table presents a cash flow summary for 2021-2022. In 2022, operating activities showed a negative cash flow of $65,993, while investing and financing activities provided positive cash flows of $517 and $11,829 respectively. The overall net change in cash for 2022 was negative $53,647, resulting in end-of-year cash equivalents of $263,180, down from $316,827 in 2021. Working capital decreased from $594,276 in 2021 to $515,359 in 2022."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 54,
          "title": "Report of Independent Registered Public Accounting Firm ~ Deloitte & Touche LLP (PCAOB ID: 34)",
          "data": [
            {
              "key": "Consolidated Balance Sheets",
              "value": "December 31, 2022 and 2021"
            },
            {
              "key": "Consolidated Statements of Operations",
              "value": "years ended December 31, 2022, 2021 and 2020"
            },
            {
              "key": "Consolidated Statements of Comprehensive (Loss) Income",
              "value": "years ended December 31, 2022, 2021 and 2020"
            },
            {
              "key": "Consolidated Statements of Stockholders' Equity",
              "value": "years ended December 31, 2022, 2021 and 2020"
            },
            {
              "key": "Consolidated Statements of Cash Flows",
              "value": "years ended December 31, 2022, 2021 and 2020"
            },
            {
              "key": "Summary",
              "value": "This table presents a list of financial statements included in an independent audit report by Deloitte & Touche LLP. The statements cover various aspects of financial reporting including balance sheets (for 2022 and 2021), and statements of operations, comprehensive income/loss, stockholders' equity, and cash flows (covering the three-year period from 2020 to 2022). This appears to be the table of contents or index for a comprehensive financial report."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 55,
          "title": "Report of Independent Registered Public Accounting Firm",
          "data": [
            {
              "key": "Company",
              "value": "NeoGenomics, Inc."
            },
            {
              "key": "Report Scope",
              "value": "Audit of consolidated financial statements including balance sheets, statements of operations, comprehensive income, stockholders’ equity and cash flows for three years ended December 31, 2022"
            },
            {
              "key": "Audit Opinion",
              "value": "Unqualified opinion on the financial statements and internal control over financial reporting"
            },
            {
              "key": "Critical Audit Matter",
              "value": "Revenue Recognition—Clinical Services and estimation of implicit price concessions based on negotiations, historical collection experience, and anticipated adjustments"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 57,
          "title": "Discount Rate Evaluation & Fair Value Assessment",
          "data": [
            {
              "key": "Document Section",
              "value": "Table of Contents and Audit Methodology"
            },
            {
              "key": "Company",
              "value": "NEOGENOMICS, INC."
            },
            {
              "key": "Evaluation Process",
              "value": "Assisted by fair value specialists, testing underlying source information and mathematical accuracy, developing a range of independent estimates, comparing discount rates selected by management with those of similar companies, and evaluating the interaction between discount rates and forecasts to assess risk assumptions."
            },
            {
              "key": "Auditor Signature",
              "value": "/s/ Deloitte & Touche LLP"
            },
            {
              "key": "Audit Location",
              "value": "San Diego, California"
            },
            {
              "key": "Audit Date",
              "value": "February 24, 2023"
            },
            {
              "key": "Auditor Relationship",
              "value": "Serving as the Company’s auditor since 2019"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 58,
          "title": "Balance Sheet",
          "data": [
            {
              "key": "Total Current Assets",
              "value": "605,291"
            },
            {
              "key": "Total Non-Current Assets",
              "value": "1,134,743"
            },
            {
              "key": "Total Assets",
              "value": "1,740,034"
            },
            {
              "key": "Total Current Liabilities",
              "value": "89,932"
            },
            {
              "key": "Total Long-Term Liabilities",
              "value": "652,079"
            },
            {
              "key": "Total Liabilities",
              "value": "742,011"
            },
            {
              "key": "Total Stockholders' Equity",
              "value": "998,023"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 59,
          "title": "Financial Performance Statement",
          "data": [
            {
              "key": "Clinical Services 2022",
              "value": "418754"
            },
            {
              "key": "Clinical Services 2021",
              "value": "404172"
            },
            {
              "key": "Clinical Services 2020",
              "value": "382337"
            },
            {
              "key": "Pharma Services 2022",
              "value": "90974"
            },
            {
              "key": "Pharma Services 2021",
              "value": "80157"
            },
            {
              "key": "Pharma Services 2020",
              "value": "62111"
            },
            {
              "key": "Total net revenue 2022",
              "value": "509728"
            },
            {
              "key": "Total net revenue 2021",
              "value": "484329"
            },
            {
              "key": "Total net revenue 2020",
              "value": "444448"
            },
            {
              "key": "COST OF REVENUE 2022",
              "value": "321832"
            },
            {
              "key": "COST OF REVENUE 2021",
              "value": "297269"
            },
            {
              "key": "COST OF REVENUE 2020",
              "value": "258555"
            },
            {
              "key": "GROSS PROFIT 2022",
              "value": "187896"
            },
            {
              "key": "GROSS PROFIT 2021",
              "value": "187060"
            },
            {
              "key": "GROSS PROFIT 2020",
              "value": "185893"
            },
            {
              "key": "NET (LOSS) INCOME 2022",
              "value": "-144250"
            },
            {
              "key": "NET (LOSS) INCOME 2021",
              "value": "-8347"
            },
            {
              "key": "NET (LOSS) INCOME 2020",
              "value": "4172"
            },
            {
              "key": "Summary",
              "value": "This table presents a comprehensive financial performance statement covering years 2020-2022. Key observations include: Total net revenue grew from $444.4M in 2020 to $509.7M in 2022; Clinical Services remains the primary revenue source, contributing about 82% of total revenue; Despite revenue growth, the company's performance deteriorated significantly, moving from a net income of $4.2M in 2020 to a substantial net loss of $144.2M in 2022; Operating expenses increased dramatically from $199.9M in 2020 to $345.5M in 2022, primarily driving the decline in profitability; Gross profit remained relatively stable across all three years, hovering around $186-188M."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 60,
          "title": "Comprehensive Income Statement",
          "data": [
            {
              "key": "NET (LOSS) INCOME",
              "value": "-144250 (2022), -8347 (2021), 4172 (2020)"
            },
            {
              "key": "Net unrealized loss on marketable securities, net of tax",
              "value": "-3261 (2022), -648 (2021), -33 (2020)"
            },
            {
              "key": "Unrealized loss on effective cash flow hedge, net of tax",
              "value": "0 (2022), 0 (2021), -1000 (2020)"
            },
            {
              "key": "Total other comprehensive (loss) income, net of tax",
              "value": "-3261 (2022), -648 (2021), 1628 (2020)"
            },
            {
              "key": "COMPREHENSIVE (LOSS) INCOME",
              "value": "-147511 (2022), -8995 (2021), 5800 (2020)"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 62,
          "title": "Cash Flow Statement Summary",
          "data": [
            {
              "key": "Net (loss) income",
              "value": "-144250"
            },
            {
              "key": "Net cash provided by operating activities (2022)",
              "value": "-65993"
            },
            {
              "key": "Net cash used in investing activities (2022)",
              "value": "517"
            },
            {
              "key": "Net cash provided by financing activities (2022)",
              "value": "11829"
            },
            {
              "key": "Net change in cash and cash equivalents (2022)",
              "value": "-53647"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 63,
          "title": "Reconciliation of cash, cash equivalents and restricted cash to the Consolidated Balance Sheets",
          "data": [
            {
              "key": "Cash and cash equivalents Restricted cash (Period 1)",
              "value": "263,180"
            },
            {
              "key": "Cash and cash equivalents Restricted cash (Period 2)",
              "value": "316,827"
            },
            {
              "key": "Cash and cash equivalents Restricted cash (Period 3)",
              "value": "228,713 21,915"
            },
            {
              "key": "Total cash, cash equivalents and restricted cash (Period 1)",
              "value": "263,180"
            },
            {
              "key": "Total cash, cash equivalents and restricted cash (Period 2)",
              "value": "316,827"
            },
            {
              "key": "Total cash, cash equivalents and restricted cash (Period 3)",
              "value": "250,632"
            },
            {
              "key": "Interest paid (Period 1)",
              "value": "3,404"
            },
            {
              "key": "Interest paid (Period 2)",
              "value": "3,065"
            },
            {
              "key": "Interest paid (Period 3)",
              "value": "2,926"
            },
            {
              "key": "Income taxes paid, net (Period 1)",
              "value": "180"
            },
            {
              "key": "Income taxes paid, net (Period 2)",
              "value": "148"
            },
            {
              "key": "Income taxes paid, net (Period 3)",
              "value": "246"
            },
            {
              "key": "Fair value of common stock acquisition (Period 2)",
              "value": "29,174"
            },
            {
              "key": "Equipment acquired under financing obligations (Period 3)",
              "value": "428"
            },
            {
              "key": "Purchases of property and equipment included in accounts payable (Period 1)",
              "value": "1,688"
            },
            {
              "key": "Purchases of property and equipment included in accounts payable (Period 2)",
              "value": "1,315"
            },
            {
              "key": "Purchases of property and equipment included in accounts payable (Period 3)",
              "value": "2,007"
            },
            {
              "key": "Table Summary",
              "value": "This table appears to be a cash flow statement showing cash positions and various cash-related transactions across three periods. The total cash and equivalents peaked at 316,827 in the second period before declining to 250,632 in the third period. Supplemental disclosures include relatively stable interest payments around 3,000 and minimal tax payments, as well as non-cash investing and financing activities such as a significant common stock acquisition valued at 29,174 in the second period."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 65,
          "title": "Summary of Significant Accounting Policies and Business Combinations",
          "data": [
            {
              "key": "ETRC Credits 2020",
              "value": "$1.9 million recognized as credits included in loss from operations"
            },
            {
              "key": "Non-Recurring Expenses",
              "value": "$4.4 million expense in 2021 and $1.9 million expense in 2020 related to non-reoccurring reversals and tax credit reserves"
            },
            {
              "key": "Segment Reporting",
              "value": "Activities reported in two segments – Clinical Services and Pharma Services – representing 100% of consolidated assets, net revenue, and net (loss) income for the years ended December 31, 2022, 2021, and 2020"
            },
            {
              "key": "Business Combinations",
              "value": "Acquisitions where control is obtained are accounted for as business combinations with assets, including identifiable intangible assets, recorded at estimated fair values with any excess purchase price recorded as goodwill"
            },
            {
              "key": "Use of Estimates & Consolidation Principles",
              "value": "Financial statements are prepared in conformity with GAAP using estimates, judgments, and assumptions; intercompany accounts are eliminated upon consolidation"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 70,
          "title": "Financial Performance and Operating Expenses Details",
          "data": [
            {
              "key": "Informatics Revenue Recognition",
              "value": "Revenue from Informatics is recognized at a point in time upon delivery of retrospective data or over time for prospective data feeds. Billing schedules and payment terms are negotiated on a contract-by-contract basis with deferred revenue recorded as contract liabilities."
            },
            {
              "key": "Cost of Revenue",
              "value": "Cost of revenue includes payroll and related costs, depreciation of laboratory equipment, facility costs, reagents, supplies, shipping costs (noted as approximately $19.6M in 2022), and amortization of intangible assets acquired from Inivata."
            },
            {
              "key": "General and Administrative Expenses",
              "value": "These expenses cover payroll for administrative functions such as billing, finance, HR, IT, professional services, facilities, depreciation, amortization and stock-based compensation."
            },
            {
              "key": "Research and Development Expenses",
              "value": "R&D costs are expensed as incurred and include payroll, laboratory supplies, equipment depreciation, and costs for validation studies, mainly aimed at developing new genetic tests."
            },
            {
              "key": "Sales and Marketing Expenses",
              "value": "Expenses are primarily due to employee-related costs for sales management, representative salaries, marketing consultants, and customer service, with advertising expenses recorded as immaterial."
            },
            {
              "key": "Restructuring Charges",
              "value": "These charges relate to a restructuring program aimed at improving execution and efficiency, including severance, employee costs, geographic optimization, and consulting expenses. Further details can be found in Note 14."
            },
            {
              "key": "Income Taxes",
              "value": "Deferred taxes are recognized for the tax consequences of temporary differences, applying enacted statutory rates to the differences between financial statement carrying amounts and the tax bases of assets."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 71,
          "title": "Tax and Financial Disclosures",
          "data": [
            {
              "key": "Deferred Taxes",
              "value": "Effect on deferred taxes due to change in tax rates recognized in the period containing the enactment date. Temporary differences arise primarily from differences in depreciation methods, recognition of bad debts, compensation related expenses, and other expenses."
            },
            {
              "key": "Provision for Income Taxes",
              "value": "Includes the effective tax rate, measurement and judgment regarding uncertain tax positions, and the recognition of interest and penalties related to unrecognized tax benefits."
            },
            {
              "key": "Uncertain Tax Positions",
              "value": "Evaluated using a two-step approach; positions are recognized if more likely than not to be sustained upon examination, and measured based on the largest amount of tax benefit likely to be realized. Includes Federal and State R&D tax credits."
            },
            {
              "key": "Net (Loss) Income per Common Share",
              "value": "Basic and diluted calculations are provided using the weighted-average number of common shares, including adjustments for potential common stock from stock options, convertible notes, and non-vested restricted stock awards."
            },
            {
              "key": "Recent Accounting Pronouncements",
              "value": "Adoption of FASB ASU No. 2021-10 (Government Assistance) and ASU No. 2021-08 (Business Combinations) with no significant impact on the Consolidated Financial Statements."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 76,
          "title": "Financial Assets Summary",
          "data": [
            {
              "key": "Table Title",
              "value": "Financial Assets Summary"
            },
            {
              "key": "Description",
              "value": "Breakdown of short-term marketable securities with amortized cost, unrealized gains/losses, and fair value as of December 31, 2022."
            },
            {
              "key": "U.S. Treasury securities Fair Value",
              "value": "55775"
            },
            {
              "key": "Yankee bonds Fair Value",
              "value": "5266"
            },
            {
              "key": "Agency bonds Fair Value",
              "value": "12369"
            },
            {
              "key": "Municipal bonds Fair Value",
              "value": "11811"
            },
            {
              "key": "Commercial paper Fair Value",
              "value": "2854"
            },
            {
              "key": "Asset-backed securities Fair Value",
              "value": "25119"
            },
            {
              "key": "Corporate bonds Fair Value",
              "value": "61615"
            },
            {
              "key": "Total Fair Value",
              "value": "174809"
            },
            {
              "key": "Total Amortized Cost",
              "value": "179248"
            },
            {
              "key": "Net Unrealized Gains/Losses",
              "value": "13 / -4452"
            },
            {
              "key": "Summary Note",
              "value": "Corporate bonds are the largest holding, followed by U.S. Treasury securities. Most securities show unrealized losses except for small gains in Commercial paper and Asset-backed securities."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 76,
          "title": "Financial Assets: Short-term Marketable Securities",
          "data": [
            {
              "key": "Table Title",
              "value": "Financial Assets: Short-term Marketable Securities"
            },
            {
              "key": "Description",
              "value": "Breakdown of short-term marketable securities as of December 31, 2021 with amortized cost, unrealized gains/losses, and fair value."
            },
            {
              "key": "U.S. Treasury securities Fair Value",
              "value": "52664"
            },
            {
              "key": "Yankee bonds Fair Value",
              "value": "6160"
            },
            {
              "key": "Agency bonds Fair Value",
              "value": "17530"
            },
            {
              "key": "Municipal bonds Fair Value",
              "value": "12229"
            },
            {
              "key": "Commercial paper Fair Value",
              "value": "17690"
            },
            {
              "key": "Asset-backed securities Fair Value",
              "value": "27535"
            },
            {
              "key": "Corporate bonds Fair Value",
              "value": "64755"
            },
            {
              "key": "Total Fair Value",
              "value": "198563"
            },
            {
              "key": "Total Amortized Cost",
              "value": "199464"
            },
            {
              "key": "Net Unrealized Gains/Losses",
              "value": "22 / -923"
            },
            {
              "key": "Summary Note",
              "value": "Corporate bonds represent the largest holding followed by U.S. Treasury securities. All security types show net unrealized losses, with corporate bonds showing the largest unrealized loss."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 77,
          "title": "Financial Assets Breakdown by Time Period",
          "data": [
            {
              "key": "One Year or Less U.S. Treasury Securities",
              "value": "40795"
            },
            {
              "key": "Over Five Years U.S. Treasury Securities",
              "value": "14980"
            },
            {
              "key": "Total U.S. Treasury Securities",
              "value": "55775"
            },
            {
              "key": "One Year or Less Yankee Bonds",
              "value": "2734"
            },
            {
              "key": "Over Five Years Yankee Bonds",
              "value": "2532"
            },
            {
              "key": "Total Yankee Bonds",
              "value": "5266"
            },
            {
              "key": "One Year or Less Agency Bonds",
              "value": "6470"
            },
            {
              "key": "Over Five Years Agency Bonds",
              "value": "5899"
            },
            {
              "key": "Total Agency Bonds",
              "value": "12369"
            },
            {
              "key": "One Year or Less Municipal Bonds",
              "value": "0"
            },
            {
              "key": "Over Five Years Municipal Bonds",
              "value": "11811"
            },
            {
              "key": "Total Municipal Bonds",
              "value": "11811"
            },
            {
              "key": "One Year or Less Commercial Paper",
              "value": "2854"
            },
            {
              "key": "Over Five Years Commercial Paper",
              "value": "0"
            },
            {
              "key": "Total Commercial Paper",
              "value": "2854"
            },
            {
              "key": "One Year or Less Asset-Backed Securities",
              "value": "23179"
            },
            {
              "key": "Over Five Years Asset-Backed Securities",
              "value": "1940"
            },
            {
              "key": "Total Asset-Backed Securities",
              "value": "25119"
            },
            {
              "key": "One Year or Less Corporate Bonds",
              "value": "35377"
            },
            {
              "key": "Over Five Years Corporate Bonds",
              "value": "26238"
            },
            {
              "key": "Total Corporate Bonds",
              "value": "61615"
            },
            {
              "key": "Total One Year or Less",
              "value": "111409"
            },
            {
              "key": "Total Over Five Years",
              "value": "63400"
            },
            {
              "key": "Grand Total",
              "value": "174809"
            },
            {
              "key": "Summary",
              "value": "This table shows the distribution of marketable securities across different time periods. Corporate bonds represent the largest holding at $61.6B, followed by U.S. Treasury securities at $55.8B. The total portfolio value is $174.8B, with $111.4B maturing in one year or less and $63.4B maturing after five years. Short-term holdings (one year or less) comprise approximately 64% of the total portfolio."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 78,
          "title": "Financial Assets by Level",
          "data": [
            {
              "key": "Money market funds",
              "value": "196749"
            },
            {
              "key": "Commercial paper (Cash equivalents)",
              "value": "36965"
            },
            {
              "key": "U.S. Treasury securities",
              "value": "55775"
            },
            {
              "key": "Yankee bonds",
              "value": "5266"
            },
            {
              "key": "Agency bonds",
              "value": "12369"
            },
            {
              "key": "Municipal bonds",
              "value": "11811"
            },
            {
              "key": "Commercial paper (Marketable securities)",
              "value": "2854"
            },
            {
              "key": "Asset-backed securities",
              "value": "25119"
            },
            {
              "key": "Corporate bonds",
              "value": "61615"
            },
            {
              "key": "Total Financial Assets",
              "value": "408523"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 78,
          "title": "Financial Assets by Fair Value Hierarchy Level",
          "data": [
            {
              "key": "Cash equivalents - Money market funds",
              "value": "254157"
            },
            {
              "key": "Cash equivalents - Commercial paper",
              "value": "22491"
            },
            {
              "key": "Marketable securities - U.S. Treasury securities",
              "value": "52664"
            },
            {
              "key": "Marketable securities - Yankee bonds",
              "value": "6160"
            },
            {
              "key": "Marketable securities - Agency bonds",
              "value": "17530"
            },
            {
              "key": "Marketable securities - Municipal bonds",
              "value": "12229"
            },
            {
              "key": "Marketable securities - Commercial paper",
              "value": "17690"
            },
            {
              "key": "Marketable securities - Asset-backed securities",
              "value": "27535"
            },
            {
              "key": "Marketable securities - Corporate bonds",
              "value": "64755"
            },
            {
              "key": "Total Financial Assets",
              "value": "475211"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 92,
          "title": "Pharma Services Contract Assets, Capitalized Commissions, and Contract Liabilities",
          "data": [
            {
              "key": "Current pharma contract assets (2022)",
              "value": "1898"
            },
            {
              "key": "Current pharma contract assets (2021)",
              "value": "1738"
            },
            {
              "key": "Long-term pharma contract assets (2022)",
              "value": "31"
            },
            {
              "key": "Long-term pharma contract assets (2021)",
              "value": "236"
            },
            {
              "key": "Total pharma contract assets (2022)",
              "value": "1929"
            },
            {
              "key": "Total pharma contract assets (2021)",
              "value": "1974"
            },
            {
              "key": "Current pharma capitalized commissions (2022)",
              "value": "800"
            },
            {
              "key": "Current pharma capitalized commissions (2021)",
              "value": "109"
            },
            {
              "key": "Long-term pharma capitalized commissions (2022)",
              "value": "715"
            },
            {
              "key": "Long-term pharma capitalized commissions (2021)",
              "value": "882"
            },
            {
              "key": "Total pharma capitalized commissions (2022)",
              "value": "1515"
            },
            {
              "key": "Total pharma capitalized commissions (2021)",
              "value": "991"
            },
            {
              "key": "Current pharma contract liabilities (2022)",
              "value": "7557"
            },
            {
              "key": "Current pharma contract liabilities (2021)",
              "value": "5192"
            },
            {
              "key": "Long-term pharma contract liabilities (2022)",
              "value": "19"
            },
            {
              "key": "Long-term pharma contract liabilities (2021)",
              "value": "917"
            },
            {
              "key": "Total pharma contract liabilities (2022)",
              "value": "7576"
            },
            {
              "key": "Total pharma contract liabilities (2021)",
              "value": "6109"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 92,
          "title": "Clinical Services and Revenue Breakdown",
          "data": [
            {
              "key": "Client direct billing (2022)",
              "value": "279732"
            },
            {
              "key": "Client direct billing (2021)",
              "value": "252617"
            },
            {
              "key": "Client direct billing (2020)",
              "value": "240535"
            },
            {
              "key": "Commercial insurance (2022)",
              "value": "73280"
            },
            {
              "key": "Commercial insurance (2021)",
              "value": "78773"
            },
            {
              "key": "Commercial insurance (2020)",
              "value": "76550"
            },
            {
              "key": "Medicare and other government (2022)",
              "value": "65585"
            },
            {
              "key": "Medicare and other government (2021)",
              "value": "72010"
            },
            {
              "key": "Medicare and other government (2020)",
              "value": "64776"
            },
            {
              "key": "Self-pay (2022)",
              "value": "157"
            },
            {
              "key": "Self-pay (2021)",
              "value": "772"
            },
            {
              "key": "Self-pay (2020)",
              "value": "476"
            },
            {
              "key": "Total Clinical Services (2022)",
              "value": "418754"
            },
            {
              "key": "Total Clinical Services (2021)",
              "value": "404172"
            },
            {
              "key": "Total Clinical Services (2020)",
              "value": "382337"
            },
            {
              "key": "Pharma Services (2022)",
              "value": "90974"
            },
            {
              "key": "Pharma Services (2021)",
              "value": "80157"
            },
            {
              "key": "Pharma Services (2020)",
              "value": "62111"
            },
            {
              "key": "Total net revenue (2022)",
              "value": "509728"
            },
            {
              "key": "Total net revenue (2021)",
              "value": "484329"
            },
            {
              "key": "Total net revenue (2020)",
              "value": "444448"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 94,
          "title": "Tax Rate Reconciliation",
          "data": [
            {
              "key": "Description",
              "value": "A reconciliation of the differences between the federal statutory tax rate (21.00%) and the effective tax rate across three periods. Notable components include state income taxes, transaction costs, penalties, compensation expense, Inivata acquisition fair value adjustment, capped call interest, tax credits, and valuation allowance adjustments."
            },
            {
              "key": "Summary",
              "value": "Effective tax rates vary from 9.46% in period1 to 129.68% in period3, with significant adjustments such as a large valuation allowance in period2 (-138.07%), substantial tax credits in period1 (132%), and a notable fair value adjustment in period2 (159.14%)."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 94,
          "title": "Deferred Tax Assets and Liabilities",
          "data": [
            {
              "key": "Description",
              "value": "Breakdown of deferred tax assets and liabilities as of December 31, 2022 and 2021, including items such as accrued compensation, net operating loss carry-forwards, tax credits, stock-based compensation, operating lease liabilities, interest expense, and adjustments related to convertible debt, research expenditures, and other items."
            },
            {
              "key": "Summary",
              "value": "Gross deferred tax assets increased significantly driven by net operating loss carry-forwards, while the valuation allowance nearly doubled. Total deferred tax assets rose slightly, whereas total deferred tax liabilities decreased notably due to reductions in intangible assets and property and equipment liabilities."
            },
            {
              "key": "Additional Info",
              "value": "At December 31, 2022, the Company reported federal net operating loss carryforwards of approximately $262.5M, foreign net operating loss carryforwards of approximately $188.9M (including $158.2M in the United Kingdom), and state net operating loss carryforwards of about $131.6M. Federal NOLs will begin expiring in 2036, with specific limitations under the Tax Act and CARES Act. Additionally, federal R&D credit carryforwards of approximately $8.1M (expiring in 2036) and state research and investment credit carryforwards of approximately $4.6M (no expiration) are reported."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 95,
          "title": "Deferred Tax Assets, Valuation Allowance, and Unrecognized Tax Benefits",
          "data": [
            {
              "key": "Valuation Allowance - Domestic Operations",
              "value": "$59.5 million"
            },
            {
              "key": "Valuation Allowance - China, Switzerland and Singapore Operations",
              "value": "$5.7 million (full valuation allowance)"
            },
            {
              "key": "Impact on Effective Tax Rate",
              "value": "Majority of unrecognized tax benefits would not impact the Company’s effective tax rate if recognized"
            },
            {
              "key": "Tax Filing Jurisdictions",
              "value": "United States, Singapore, Switzerland, China, United Kingdom and various state jurisdictions"
            },
            {
              "key": "Open Tax Years (U.S.)",
              "value": "December 31, 2017 to December 31, 2022"
            },
            {
              "key": "IRS Examination",
              "value": "2017 U.S. Federal income tax filing is under examination"
            },
            {
              "key": "EPS Reporting",
              "value": "Both basic and diluted EPS are presented; diluted EPS includes potential dilution from convertible notes and stock awards"
            },
            {
              "key": "Unrecognized Tax Benefits Table Summary",
              "value": "The table details movements in unrecognized tax benefits; increases driven primarily by current year tax positions and prior year positions with a final balance increase of approximately 34% year-over-year"
            },
            {
              "key": "Table Data - Unrecognized Tax Benefits (in thousands)",
              "value": "January 1: [Period1=2351, Period2=1670], Increases in prior year positions: [Period1=82, Period2=83], Increases in current year positions: [Period1=726, Period2=632], Statute expirations: [Period1=0, Period2=-64], December 31: [Period1=3159, Period2=2351]"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 96,
          "title": "NEOGENOMICS, INC. Earnings, Dilutive Shares & Related Financial Metrics",
          "data": [
            {
              "key": "Net (Loss) Income 2022",
              "value": "-144250"
            },
            {
              "key": "Net (Loss) Income 2021",
              "value": "-8347"
            },
            {
              "key": "Net (Loss) Income 2020",
              "value": "4172"
            },
            {
              "key": "Basic Weighted Average Common Shares Outstanding 2022",
              "value": "124217"
            },
            {
              "key": "Basic Weighted Average Common Shares Outstanding 2021",
              "value": "119962"
            },
            {
              "key": "Basic Weighted Average Common Shares Outstanding 2020",
              "value": "108579"
            },
            {
              "key": "Diluted Weighted Average Shares Outstanding 2022",
              "value": "124217"
            },
            {
              "key": "Diluted Weighted Average Shares Outstanding 2021",
              "value": "119962"
            },
            {
              "key": "Diluted Weighted Average Shares Outstanding 2020",
              "value": "111794"
            },
            {
              "key": "Basic Net (Loss) Income per Share 2022",
              "value": "-1.16"
            },
            {
              "key": "Basic Net (Loss) Income per Share 2021",
              "value": "-0.07"
            },
            {
              "key": "Basic Net (Loss) Income per Share 2020",
              "value": "0.04"
            },
            {
              "key": "Diluted Net (Loss) Income per Share 2022",
              "value": "-1.16"
            },
            {
              "key": "Diluted Net (Loss) Income per Share 2021",
              "value": "-0.07"
            },
            {
              "key": "Diluted Net (Loss) Income per Share 2020",
              "value": "0.04"
            },
            {
              "key": "Excluded Dilutive Shares - Stock Options 2022",
              "value": "199"
            },
            {
              "key": "Excluded Dilutive Shares - Stock Options 2021",
              "value": "1892"
            },
            {
              "key": "Excluded Dilutive Shares - Restricted Stock Awards 2022",
              "value": "312"
            },
            {
              "key": "Excluded Dilutive Shares - Restricted Stock Awards 2021",
              "value": "194"
            },
            {
              "key": "Excluded Dilutive Shares - 2025 Convertible Notes 2022",
              "value": "5538"
            },
            {
              "key": "Excluded Dilutive Shares - 2025 Convertible Notes 2021",
              "value": "5538"
            },
            {
              "key": "Excluded Dilutive Shares - 2025 Convertible Notes 2020",
              "value": "3723"
            },
            {
              "key": "2028 Convertible Notes",
              "value": "5215 (col1), 5130 (col2)"
            },
            {
              "key": "Defined Contribution 401(k) Match - 2022",
              "value": "$7.1M"
            },
            {
              "key": "Defined Contribution 401(k) Match - 2021",
              "value": "$6.1M"
            },
            {
              "key": "Defined Contribution 401(k) Match - 2020",
              "value": "$4.9M"
            },
            {
              "key": "Purchase Commitments",
              "value": "$1.0M (expiring in 2023)"
            },
            {
              "key": "Legal Proceedings",
              "value": "Patent infringement complaints filed by Natera, Inc. in Jan 2021 and Dec 2022"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 98,
          "title": "Table of Contents",
          "data": [
            {
              "key": "Company",
              "value": "NEOGENOMICS, INC."
            },
            {
              "key": "Revenue Information",
              "value": "Consolidated Statements of Operations for the years ended December 31, 2022 and 2021 are presented; revenue for the year ended December 31, 2020 was immaterial in connection with these contracts."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 99,
          "title": "Net revenue and Financial Statement",
          "data": [
            {
              "key": "Clinical Services Net Revenue 2022",
              "value": "418754"
            },
            {
              "key": "Clinical Services Net Revenue 2021",
              "value": "404172"
            },
            {
              "key": "Clinical Services Net Revenue 2020",
              "value": "382337"
            },
            {
              "key": "Pharma Services Net Revenue 2022",
              "value": "90974"
            },
            {
              "key": "Pharma Services Net Revenue 2021",
              "value": "80157"
            },
            {
              "key": "Pharma Services Net Revenue 2020",
              "value": "62111"
            },
            {
              "key": "Total Net Revenue 2022",
              "value": "509728"
            },
            {
              "key": "Total Net Revenue 2021",
              "value": "484329"
            },
            {
              "key": "Total Net Revenue 2020",
              "value": "444448"
            },
            {
              "key": "Clinical Services Cost 2022",
              "value": "261742"
            },
            {
              "key": "Clinical Services Cost 2021",
              "value": "244360"
            },
            {
              "key": "Clinical Services Cost 2020",
              "value": "215529"
            },
            {
              "key": "Pharma Services Cost 2022",
              "value": "60090"
            },
            {
              "key": "Pharma Services Cost 2021",
              "value": "52909"
            },
            {
              "key": "Pharma Services Cost 2020",
              "value": "43026"
            },
            {
              "key": "Total Cost of Revenue 2022",
              "value": "321832"
            },
            {
              "key": "Total Cost of Revenue 2021",
              "value": "297269"
            },
            {
              "key": "Total Cost of Revenue 2020",
              "value": "258555"
            },
            {
              "key": "Loss Before Taxes 2022",
              "value": "-159342"
            },
            {
              "key": "Loss Before Taxes 2021",
              "value": "-15075"
            },
            {
              "key": "Loss Before Taxes 2020",
              "value": "-14056"
            },
            {
              "key": "Income Tax Benefit 2022",
              "value": "-15092"
            },
            {
              "key": "Income Tax Benefit 2021",
              "value": "-6728"
            },
            {
              "key": "Income Tax Benefit 2020",
              "value": "-18228"
            },
            {
              "key": "Summary",
              "value": "The financial statement presents segmented revenue and cost information for Clinical and Pharma Services over the periods ending December 31, 2022, 2021, and 2020. Despite overall revenue growth, the company has experienced significant operating losses and has recorded tax benefits in each period."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 101,
          "title": "Opinion on Internal Control over Financial Reporting",
          "data": [
            {
              "key": "Company",
              "value": "NeoGenomics, Inc. and subsidiaries"
            },
            {
              "key": "Audit Basis",
              "value": "Internal Control — Integrated Framework (2013) issued by COSO"
            },
            {
              "key": "Audit Date",
              "value": "December 31, 2022"
            },
            {
              "key": "Financial Statements Period",
              "value": "Year ended December 31, 2022"
            },
            {
              "key": "Report Date",
              "value": "February 24, 2023"
            },
            {
              "key": "Audit Opinion",
              "value": "Unqualified opinion on both internal control over financial reporting and the consolidated financial statements"
            },
            {
              "key": "Auditor",
              "value": "Deloitte & Touche LLP"
            },
            {
              "key": "Location",
              "value": "San Diego, California"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 139,
          "title": "Consent of Independent Registered Public Accounting Firm",
          "data": [
            {
              "key": "Date of Report",
              "value": "February 24, 2023"
            },
            {
              "key": "Company",
              "value": "NeoGenomics, Inc."
            },
            {
              "key": "Report Type",
              "value": "Annual Report on Form 10-K"
            },
            {
              "key": "Financial Year Ended",
              "value": "December 31, 2022"
            },
            {
              "key": "Accounting Firm",
              "value": "Deloitte & Touche LLP"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_dividend_policy_changes": {
      "value": false,
      "elements": []
    },
    "has_share_buyback_plans": {
      "value": true,
      "elements": [
        {
          "type": "share_buyback",
          "page": 38,
          "title": "Share Repurchase Activity Report & Leadership Appointments",
          "data": [
            {
              "key": "Employee Stock Purchase Plan Amendment",
              "value": "Increased maximum shares reserved for issuance to 2,500,000 on June 2, 2022"
            },
            {
              "key": "2022 Inducement Agreements",
              "value": "Maximum shares reserved available under inducement agreements is 1,679,641"
            },
            {
              "key": "CEO Appointment",
              "value": "Mr. Christopher M. Smith appointed effective August 15, 2022"
            },
            {
              "key": "CFO Appointment",
              "value": "Mr. Jeffrey S. Sherman appointed effective December 5, 2022"
            },
            {
              "key": "Share Repurchase - October 2022",
              "value": "67 shares purchased at an average price of $8.10"
            },
            {
              "key": "Share Repurchase - November 2022",
              "value": "15 shares purchased at an average price of $10.43"
            },
            {
              "key": "Share Repurchase - December 2022",
              "value": "22,546 shares purchased at an average price of $9.24"
            },
            {
              "key": "Total Shares Repurchased",
              "value": "22,628 shares purchased over the period October 1, 2022 to December 31, 2022"
            },
            {
              "key": "Additional Context",
              "value": "Share purchases were executed outside of a publicly-announced repurchase program to satisfy tax withholding obligations related to the vesting of restricted shares."
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_capital_structure_changes": {
      "value": true,
      "elements": [
        {
          "type": "capital_structure",
          "page": 61,
          "title": "Statement of Stockholders' Equity Changes (2019-2022)",
          "data": [
            {
              "key": "December 31, 2019",
              "value": "Common Shares: 104781236, Stock Amount: 105, Additional Paid-In Capital: 520278, Comprehensive Income/Loss: -1618, Accumulated Deficit: -11357, Total: 307408"
            },
            {
              "key": "December 31, 2020",
              "value": "Common Shares: 112075474, Stock Amount: 112, Additional Paid-In Capital: 701357, Comprehensive Income/Loss: 10, Accumulated Deficit: -7185, Total: 694294"
            },
            {
              "key": "December 31, 2021",
              "value": "Common Shares: 124107500, Stock Amount: 124, Additional Paid-In Capital: 1123628, Comprehensive Income/Loss: -638, Accumulated Deficit: -14837, Total: 1108277"
            },
            {
              "key": "December 31, 2022",
              "value": "Common Shares: 126913992, Stock Amount: 127, Additional Paid-In Capital: 1160882, Comprehensive Income/Loss: -3899, Accumulated Deficit: -159087, Total: 998023"
            },
            {
              "key": "Summary",
              "value": "The table shows changes in stockholders' equity from 2019 to 2022. Notable trends: increase in common shares from 104.8M to 126.9M, significant growth in additional paid-in capital from $520M to $1.16B, net losses in 2022, and overall increase in total stockholders' equity despite losses. Major changes include public offerings, stock-based compensation, and convertible note issuances."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_structure",
          "page": 85,
          "title": "Convertible Notes and Capital Structure Details",
          "data": [
            {
              "key": "2028 Convertible Notes Interest Expense 2022",
              "value": "Contractual coupon: $0.9M, Debt discount amortization: $1.5M, Issuance costs amortization: $34K"
            },
            {
              "key": "2028 Convertible Notes Interest Expense 2021",
              "value": "Contractual coupon: $0.8M, Debt discount amortization: $1.4M, Issuance costs amortization: $32K"
            },
            {
              "key": "Effective Interest Rate (2028 Notes)",
              "value": "0.70% (includes interest, discount and issuance costs)"
            },
            {
              "key": "Coupon Rate (2028 Notes)",
              "value": "0.25% per annum, payable semi-annually on January 15 and July 15"
            },
            {
              "key": "Capped Call Transactions",
              "value": "Entered Jan 11, 2021 at a cost of approximately $29.3M; covers 5.2M shares with an initial cap price of $85.75 per share"
            },
            {
              "key": "2025 Convertible Senior Notes",
              "value": "Issued on May 4, 2020 for $201.3M at 97.0% of principal, with a stated interest rate of 1.25% and maturity on May 1, 2025"
            },
            {
              "key": "Conversion Conditions (2025 Notes)",
              "value": "Conversion options available under specified conditions relating to common stock sale price and corporate events"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_structure",
          "page": 86,
          "title": "Convertible Notes Terms and Classification",
          "data": [
            {
              "key": "Company",
              "value": "NEOGENOMICS, INC."
            },
            {
              "key": "Notes Classification",
              "value": "Classified as long-term debt as of December 31, 2022 and 2021"
            },
            {
              "key": "Conversion Notice Period",
              "value": "Holders cannot convert in first quarter of 2023"
            },
            {
              "key": "Conversion Options",
              "value": "Upon conversion, the Company may pay/deliver cash, common stock, or a combination"
            },
            {
              "key": "Initial Conversion Rate",
              "value": "27.5198 shares per $1,000 principal"
            },
            {
              "key": "Initial Conversion Price",
              "value": "$36.34 per share"
            },
            {
              "key": "Conversion Rate Adjustments",
              "value": "Subject to adjustment as described in the Indenture; include make-whole premium for certain corporate events"
            },
            {
              "key": "Closing Stock Price Reference",
              "value": "$9.24 on December 31, 2022"
            },
            {
              "key": "Redemption Eligibility",
              "value": "May redeem on or after May 6, 2023 if common stock price ≥ 130% of conversion price for specified period"
            },
            {
              "key": "Default and Acceleration Provisions",
              "value": "Upon bankruptcy, default or fundamental change events, principal plus accrued interest may become immediately due"
            },
            {
              "key": "Subordination",
              "value": "Convertible Notes are senior, unsecured, equal in right of payment to existing/future senior unsecured indebtedness, but structurally subordinated to all existing and future indebtedness of subsidiaries"
            },
            {
              "key": "Interest Expense 2022",
              "value": "Contractual coupon interest $2.5M; amortization of debt discount $1.2M; amortization of debt issuance costs $0.1M"
            },
            {
              "key": "Interest Expense 2021",
              "value": "Contractual coupon interest $2.5M; amortization of debt discount $1.2M; amortization of debt issuance costs $0.1M"
            },
            {
              "key": "Effective Interest Rate",
              "value": "1.96%"
            },
            {
              "key": "Coupon Interest Rate",
              "value": "1.25% per annum, payable semi-annually on May 1 and November 1"
            },
            {
              "key": "Debt Issuance Start",
              "value": "Began on November 1, 2020"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_structure",
          "page": 87,
          "title": "Long-Term Debt Breakdown",
          "data": [
            {
              "key": "Year 023",
              "value": "notes_1: 0, notes_2: 0, equipment_financing: 70, total: 70"
            },
            {
              "key": "Year 025",
              "value": "notes_1: 0, notes_2: 201,250, equipment_financing: 0, total: 201,250"
            },
            {
              "key": "Year Thereafter",
              "value": "notes_1: 345,000, notes_2: 0, equipment_financing: 0, total: 345,000"
            },
            {
              "key": "Total Debt",
              "value": "notes_1: 345,000, notes_2: 201,250, equipment_financing: 70, total: 546,320"
            },
            {
              "key": "Less: Current portion",
              "value": "notes_1: 0, notes_2: 0, equipment_financing: (70), total: (70)"
            },
            {
              "key": "Less: Unamortized debt discount",
              "value": "notes_1: (7,505), notes_2: (2,891), equipment_financing: 0, total: (10,396)"
            },
            {
              "key": "Less: Unamortized debt issuance costs",
              "value": "notes_1: (174), notes_2: (358), equipment_financing: 0, total: (532)"
            },
            {
              "key": "Long-term debt, net",
              "value": "notes_1: 337,321, notes_2: 198,001, equipment_financing: 0, total: 535,322"
            },
            {
              "key": "Summary",
              "value": "The table provides a detailed breakdown of long-term debt maturities as of December 31, 2022, with total debt of $546,320 (in thousands) and net long-term debt of $535,322 after deducting current portion, unamortized debt discount, and issuance costs."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_structure",
          "page": 103,
          "title": "Exhibit Index",
          "data": [
            {
              "key": "Description",
              "value": "This exhibit index lists various corporate documents filed with the SEC, including Articles of Incorporation, Amended and Restated Bylaws, indentures, convertible notes, registration rights agreements, and an Equity Incentive Plan."
            },
            {
              "key": "SEC Filing References",
              "value": "References include the Company's Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and Current Report on Form 8-K."
            },
            {
              "key": "Document Periods",
              "value": "Documents and agreements span from 2005 through 2021."
            },
            {
              "key": "Relevant Instruments",
              "value": "Includes convertible notes (1.25% due 2025 and 0.25% due 2028) and related indentures, which pertain to the company's capital structure."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "mentions_new_risk_factors": {
      "value": true,
      "elements": [
        {
          "type": "risk_factor",
          "page": 9,
          "title": "Risk Factors, Competition and Supply Chain Disruptions",
          "data": [
            {
              "key": "Company",
              "value": "NEOGENOMICS, INC."
            },
            {
              "key": "Clinical Trial Enrollment",
              "value": "Highly dependent on Pharma clinical trial enrollment recovering from COVID-19 slowdown"
            },
            {
              "key": "Competition",
              "value": "Intense competition in the Clinical Services segment from major national medical testing labs, hospital labs and in-house physician labs; competitors may possess superior financial resources and production capabilities."
            },
            {
              "key": "Service Segments",
              "value": "Clinical Services and Pharma Services with emphasis on rapid turnaround, broad service menu, high-quality test reports and specialized platforms like MultiOmyx™"
            },
            {
              "key": "Supply Chain Disruptions",
              "value": "Experienced increased supply chain disruptions and delays in obtaining reagents and laboratory supplies in 2021 and 2022, potentially affecting turnaround times and gross margins."
            },
            {
              "key": "Credit Risk Concentration",
              "value": "Risk concentrated in revenues from specific clients and payers (e.g., Medicare and insurance companies)"
            },
            {
              "key": "Client Dependency",
              "value": "Diversified client base with no single client exceeding 10% of revenue, though reliance on major clients persists."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 16,
          "title": "Risk Factors and Privacy Compliance",
          "data": [
            {
              "key": "Privacy Laws",
              "value": "The document details various international privacy laws, including Singapore's PDPA and China's PIPL, which, similar to HIPAA, require robust data privacy and security programs and mandate breach reporting."
            },
            {
              "key": "Penalties",
              "value": "Highlights severe penalties under regulations such as GDPR, with fines up to the greater of 4.0% of annual global turnover or €20.0 million."
            },
            {
              "key": "International Data Collection",
              "value": "Indicates that the Company collects data internationally as part of its Pharma business, subjecting it to compliance with multiple jurisdictional privacy laws."
            },
            {
              "key": "Risk Factors Summary",
              "value": "Discusses a range of risk factors including rapid scientific change, capacity constraints, increased competition, delays in new product development, litigation risks, reliance on third parties, and potential cybersecurity breaches."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 18,
          "title": "Risk Factors and Business Challenges - NEOGENOMICS, INC.",
          "data": [
            {
              "key": "Integration Risk",
              "value": "Failure to successfully integrate future acquisitions with legacy operations may prevent realization of anticipated benefits."
            },
            {
              "key": "Goodwill Impairment",
              "value": "Recorded goodwill and intangible assets from acquisitions may become impaired, potentially leading to significant charges against earnings."
            },
            {
              "key": "Cost Overruns and Losses",
              "value": "There is a risk of incurring greater costs than anticipated, which could result in sustained losses."
            },
            {
              "key": "Operational and Seasonal Fluctuations",
              "value": "Fluctuations in results of operations due to seasonality and other factors could negatively affect business operations."
            },
            {
              "key": "Intellectual Property Concerns",
              "value": "Inadequate protection of proprietary rights may lead to infringement or misappropriation by third parties."
            },
            {
              "key": "Rapid Scientific Change",
              "value": "The business is subject to rapid scientific developments and evolving industry standards, which may adversely impact results of operations and financial condition."
            },
            {
              "key": "Capacity Constraints",
              "value": "Unexpected increases in client volume could strain personnel and infrastructure, leading to delays and diminished customer service."
            },
            {
              "key": "Competitive Pressure",
              "value": "Intensifying competition, including advances by competitors in testing and technology, may negatively impact net revenues and profitability."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 20,
          "title": "Risk Factors and Legal Exposure",
          "data": [
            {
              "key": "Litigation Risks",
              "value": "The document outlines potential litigation claims that could exceed insurance coverage, involve various types of legal proceedings (employment, commercial, product liability, class action, whistleblower, and regulatory investigations), and have a material adverse effect on business operations."
            },
            {
              "key": "Clinical Trials Liability",
              "value": "There is risk related to clinical trials and research services including potential errors or omissions which may harm study volunteers, delay drug market entry, and affect the usefulness of trial data."
            },
            {
              "key": "Investment Risks",
              "value": "Investments in marketable securities are subject to risks that could impair liquidity or cause losses, thereby affecting overall financial condition and operating results."
            },
            {
              "key": "Product Supply and Recall Risk",
              "value": "Reliance on third-party manufacturers for reagents, test kits, and instruments is highlighted, including risks from discontinuations or recalls which could adversely affect costs, testing volume, and revenues."
            },
            {
              "key": "Dependence on Third-Party Payments",
              "value": "The document mentions reliance on third-party payers, such as insurance companies and government programs, with the associated risk of delayed or insufficient payments impacting cash flows and operations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 21,
          "title": "Risk Factors Related to Service Provision and Operations",
          "data": [
            {
              "key": "Impact of non-participating provider status",
              "value": "Non-participating providers have no contractual assurance of payment, potentially adversely affecting cash flow."
            },
            {
              "key": "Issues with CPT codes recognition",
              "value": "Delays in recognition of new CPT codes by insurers can impact payment timing and increase accounts receivable."
            },
            {
              "key": "Insurance company behavior",
              "value": "Insurance companies may steer business to in-network providers, affecting client acquisition."
            },
            {
              "key": "Physical damage risks",
              "value": "Operations are at risk of physical damage from various disasters, which may disrupt services."
            },
            {
              "key": "Cybersecurity vulnerabilities",
              "value": "Cyber-attacks could affect operations and personal data protection, leading to legal and regulatory consequences."
            },
            {
              "key": "Dependence on technology systems",
              "value": "Laboratory operations rely on IT systems, whose failure could disrupt service delivery."
            },
            {
              "key": "Shipping carrier reliability",
              "value": "Dependent on FedEx for transport; performance issues could impact service reliability and reputation."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 22,
          "title": "Risk Factors Pertaining to Operations and Financial Condition",
          "data": [
            {
              "key": "Shipping Rates Impact",
              "value": "Any significant increase in shipping rates could adversely affect operating margins and results of operations."
            },
            {
              "key": "Service Interruptions",
              "value": "Strikes, severe weather, natural disasters, or other delivery service interruptions could delay the receipt and processing of patient samples."
            },
            {
              "key": "Provider Termination Risk",
              "value": "If the current carrier relationship is terminated, finding a new expedited and reliable transport provider may be time-consuming, costly, and uncertain."
            },
            {
              "key": "Hazardous Materials Handling",
              "value": "The use of biological and hazardous materials involves significant handling, storage, and disposal costs and risks, potentially exposing the company to claims and environmental liabilities."
            },
            {
              "key": "Regulatory Compliance Risk",
              "value": "Compliance with environmental laws and regulations is expensive; failure to comply may result in fines, penalties, or operational suspension."
            },
            {
              "key": "Stock Price Volatility",
              "value": "Factors such as leadership changes, regulatory developments, and market fluctuations could lead to significant volatility in the common stock price."
            },
            {
              "key": "Convertible Notes Cash Flow Risk",
              "value": "Servicing Convertible Notes requires significant cash flow, which might not be available from operations, adversely affecting financial condition and results."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 24,
          "title": "Risks Relating to Government Regulation and Reimbursement",
          "data": [
            {
              "key": "Company",
              "value": "NEOGENOMICS, INC."
            },
            {
              "key": "Risk Description",
              "value": "Regulatory changes concerning Laboratory Developed Tests (LDTs) may require additional clinical trials, result in delays, increase costs, and impose a heavier regulatory burden, impacting both current and future diagnostic test offerings."
            },
            {
              "key": "FDA Oversight",
              "value": "The FDA has proposed frameworks (including draft guidance and discussion papers) that could necessitate premarket approval or clearance for certain LDTs, adding complexity and cost."
            },
            {
              "key": "Legislative Uncertainty",
              "value": "Potential legislative measures, such as the VALID Act, and shifting policies during the COVID-19 public health emergency contribute to uncertainty regarding regulatory requirements."
            },
            {
              "key": "Business Impact",
              "value": "Increased regulatory burdens could delay commercialization, elevate development costs, and risk the ability to maintain market presence for current tests."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 25,
          "title": "Risk Factors in Healthcare Reform and Reimbursement",
          "data": [
            {
              "key": "Clinical Protocol Adherence",
              "value": "Failures to adhere to clinical protocols can compromise data accuracy and may lead to extensions, delays, or termination of clinical trials, increasing R&D costs."
            },
            {
              "key": "Healthcare Reform Impact",
              "value": "Legislation such as the Patient Protection and Affordable Care Act (ACA) and changes to healthcare reimbursement policies (e.g., Medicare’s MPFS, CLFS) pose risks to the business by potentially decreasing revenue."
            },
            {
              "key": "Legislative and Regulatory Uncertainty",
              "value": "Ongoing efforts to repeal or modify the ACA, along with new changes from laws like MACRA and PAMA, create an uncertain regulatory environment that may adversely affect reimbursement rates and operational results."
            },
            {
              "key": "Third-Party Payer Challenges",
              "value": "Reliance on non-contracted agreements with third-party payers and subsequent adjustments in contractual allowances can negatively impact revenue and financial performance."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 26,
          "title": "Medicare Reimbursement Reductions and Regulatory Changes",
          "data": [
            {
              "key": "Reduction Caps",
              "value": "Reimbursements capped at 10.0% per annum (2017-2020), increased to 15.0% for 2020; delayed implementation with 0.0% for 2021-2022; further delayed to 2024 and extended through 2026"
            },
            {
              "key": "Legislative Acts",
              "value": "Coronavirus Aid, Relief, and Economic Security Act (CARES Act), Protecting Medicare and American Farmers from Sequester Cuts Act, Consolidated Appropriations Act 2023"
            },
            {
              "key": "CMS Regulations",
              "value": "Convergence of Medicare CLFS reimbursement rate towards median private payer rate; evolving coverage rules including national coverage analysis and decisions on NGS diagnostic tests"
            },
            {
              "key": "Potential Financial Impact",
              "value": "Reduced Medicare program payments for CLFS tests; potential for further reductions and recoupment of payments if tests do not meet coverage criteria; increased administrative complexities and costs due to regulatory changes"
            },
            {
              "key": "Managed Care Trends",
              "value": "Shift of Medicare and Medicaid fee-for-service beneficiaries to managed care programs, requiring new contracting arrangements"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 27,
          "title": "Regulatory, Compliance and Reimbursement Risks",
          "data": [
            {
              "key": "Regulatory Oversight",
              "value": "The document highlights extensive federal, state, and local regulatory oversight, including requirements under CLIA, state licensing laws, OSHA, and the Needlestick Safety and Prevention Act."
            },
            {
              "key": "Compliance Requirements",
              "value": "Laboratories must maintain appropriate CLIA Certificates and state licenses, and are subject to periodic inspections and surveys to ensure compliance with applicable standards."
            },
            {
              "key": "Risk of Non-Compliance",
              "value": "Failure to comply with relevant laws and regulations may result in fines, penalties, corrective action plans, loss of licensure, and other sanctions that could materially adversely affect the business, results of operations, and financial condition."
            },
            {
              "key": "Reimbursement Challenges",
              "value": "The text discusses the pressure on reimbursement rates due to managed care initiatives, government efforts to control healthcare costs, and scrutiny from third-party payers, potentially reducing revenue."
            },
            {
              "key": "Impact of Legislative Changes",
              "value": "Future changes in laws or regulations and new legislative measures may impose additional requirements or cost pressures, further impacting operational and financial results."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 28,
          "title": "Billing and Compliance Risks (False Claims Act Exposure)",
          "data": [
            {
              "key": "Company",
              "value": "NEOGENOMICS, INC."
            },
            {
              "key": "Billing Complexity",
              "value": "Third-party billing is highly complicated with various payers (patients, insurers, Medicare, Medicaid, etc.) each having different billing requirements."
            },
            {
              "key": "Compliance and Audits",
              "value": "Internal audits and routine external audits by insurers and government agencies are conducted to ensure compliance with federal and state laws and regulations."
            },
            {
              "key": "Regulatory Risks",
              "value": "Non-compliance with documentation, coding, and billing rules may result in liability under the federal False Claims Act and similar state laws."
            },
            {
              "key": "Potential Consequences",
              "value": "Risks include substantial penalties, civil fines, loss of licenses, exclusion from government programs, and costly legal disputes."
            },
            {
              "key": "Cost Factors",
              "value": "Additional costs stem from complex billing processes, the need for specialized training, implementing compliance procedures, and managing collections and legal expenses."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 30,
          "title": "Regulatory Compliance Risk Factors and Potential Penalties",
          "data": [
            {
              "key": "Regulatory Compliance",
              "value": "Failure to comply with applicable Medicare, Medicaid, and other governmental payer rules may result in significant financial penalties and exclusion from government programs."
            },
            {
              "key": "Stark Law",
              "value": "Violations can lead to denial of payment for DHS services, repayment of amounts, and substantial civil monetary penalties, impacting the company's operations and revenue."
            },
            {
              "key": "Anti-Kickback Statute (AKS)",
              "value": "Violations, even without specific intent, may trigger criminal fines, imprisonment, civil penalties, and false claims liability, significantly affecting revenue."
            },
            {
              "key": "False Claims Act",
              "value": "Non-compliance with fraud and abuse laws may expose the company to liability under the False Claims Act, including potential qui tam actions."
            },
            {
              "key": "Operational and Financial Impact",
              "value": "Non-compliance with regulatory requirements can result in limitations on operations, structural modifications, and a material adverse effect on results of operations and financial condition."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 31,
          "title": "Risk Factors: Regulatory and Compliance Risks",
          "data": [
            {
              "key": "Anti-Kickback Laws",
              "value": "Discussion of anti-kickback statutes that prohibit remuneration for referrals, with potential penalties including fines, exclusion from programs, and contractual termination."
            },
            {
              "key": "Corporate Practice of Medicine",
              "value": "Consideration of state laws prohibiting corporate practice of medicine, impacting service agreements with physicians and professional associations."
            },
            {
              "key": "HIPAA Compliance",
              "value": "Overview of HIPAA regulations and state privacy laws governing electronic health information, with risks of non-compliance leading to fines, penalties, and reputational damage."
            },
            {
              "key": "Breach Notification and Remediation",
              "value": "Risks related to breach notification requirements, including potential operational and financial costs and the need for remedial actions."
            },
            {
              "key": "Material Adverse Effects",
              "value": "The potential for significant business disruptions, loss of revenue, and adverse impacts due to non-compliance with these regulatory frameworks."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 32,
          "title": "NEOGENOMICS, INC. sanctions for a breach & Data Security Risks",
          "data": [
            {
              "key": "Risk Overview",
              "value": "The document details risks related to security breaches including interruptions in service, reputational damage, fines, and potential liability due to unauthorized access, computer viruses, and cyber-attacks."
            },
            {
              "key": "Compliance and Regulatory Environment",
              "value": "It highlights compliance requirements with HIPAA, the Information Blocking Rules under the 21st Century Cures Act, various federal and state privacy laws, and additional regulations such as genetic testing laws."
            },
            {
              "key": "International Data Protection Concerns",
              "value": "The text discusses GDPR obligations, limitations on international data transfers, and the impact of legal decisions like Schrems II on using standard contractual clauses."
            },
            {
              "key": "Potential Consequences",
              "value": "Consequences of breaches include fines, loss of clients, direct damages, repair and detection costs, and increased operating expenses due to non-compliance with evolving data security laws."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 33,
          "title": "Risk Factors and Business Challenges",
          "data": [
            {
              "key": "Regulatory Risk",
              "value": "Uncertainty regarding the implementation and enforcement of personal data transfer clauses under GDPR and other international data protection laws (FADP, PDPA, PIPL); potential for additional costs, regulatory investigations, or fines."
            },
            {
              "key": "Pandemic Impact",
              "value": "Significant volatility in operations and testing volumes due to the COVID-19 pandemic, leading to disruptions in business, reduced revenues, and overall uncertainty in restoring normal economic conditions."
            },
            {
              "key": "Operational Risk",
              "value": "Potential business disruptions caused by changing regulatory guidance and the evolving nature of global health crises, including challenges related to supplier reliability and distribution channels."
            },
            {
              "key": "Personnel and Sales Risk",
              "value": "Dependence on key personnel and challenges in recruiting and retaining highly qualified management, technical staff, and sales representatives; risks of decreased performance and inability to expand market presence."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 34,
          "title": "Risk Factors and Operational Challenges",
          "data": [
            {
              "key": "Sales Representative Termination Risk",
              "value": "The document highlights the risk that if a sales representative ceases employment, it could lead to the loss of client goodwill and may allow competitors to benefit from established relationships."
            },
            {
              "key": "Compliance and Legal Risks",
              "value": "Non-compliant activities by sales and marketing personnel may result in significant liabilities under regulations such as the AKS, along with risks associated with unlawful conduct."
            },
            {
              "key": "Data Security and Privacy Risks",
              "value": "The text outlines risks related to failing to comply with privacy laws and information security policies. This includes potential data breaches involving sensitive patient and personal information, leading to fines, penalties, and reputational damage."
            },
            {
              "key": "Restructuring and Cost Reduction Risks",
              "value": "Ongoing restructuring and cost reduction activities present risks, including potential service disruptions, loss of key relationships, and challenges in realizing expected efficiencies and benefits."
            },
            {
              "key": "Acquisition Integration Risk",
              "value": "There is a risk that failure to successfully integrate future acquisitions with the existing business could prevent the realization of anticipated benefits, adversely affecting overall operations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 36,
          "title": "Properties & Risk Factors",
          "data": [
            {
              "key": "Operational Risks",
              "value": "Future sales and operating results are difficult to forecast due to seasonality, pricing changes, economic conditions, and unexpected revenue shortfalls which could have an immediate adverse impact on business and financial condition."
            },
            {
              "key": "Intellectual Property Risk",
              "value": "The measures taken to protect proprietary rights such as copyrights, trademarks, trade secrets may be inadequate, exposing the company to potential infringement or misappropriation by third parties."
            },
            {
              "key": "Property Assets",
              "value": "The company operates an international network of laboratories with leases expiring through 2041. The facilities are deemed sufficient for current needs and include laboratories and administrative offices."
            },
            {
              "key": "Facilities Table",
              "value": "Fort Myers, FL: 150000; Aliso Viejo, CA: 112700; Houston, TX: 32800; Carlsbad, CA: 28600; San Diego, CA: 25400; Durham, NC: 14500; Cambridge, UK: 12500; Geneva (Rolle), Switzerland: 8000; Nashville, TN: 7800; Tampa, FL: 5600; Phoenix, AZ: 4700; Chicago, IL: 4600; Singapore: 4000; Atlanta, GA: 3800; Suzhou, China: 3400; Fresno, CA: 2600"
            },
            {
              "key": "Segment Support",
              "value": "Locations in Nashville, Tampa, Atlanta, and Phoenix support the Clinical Services segment exclusively, while laboratories in Rolle, Singapore, and Suzhou support the Pharma Services segment."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 53,
          "title": "Foreign Currency Exchange Risk",
          "data": [
            {
              "key": "Market Exposure",
              "value": "NEOGENOMICS, INC. is exposed to risks from sudden changes in market interest rates and adverse changes in marketable securities’ values."
            },
            {
              "key": "Foreign Currency Risk",
              "value": "The company has operations in Cambridge (UK), Rolle (Switzerland), Singapore, and Suzhou (China). International revenues and expenses are denominated in British Pounds, Swiss Francs, Singapore Dollars, and Chinese Yuan, exposing the company to fluctuations against the U.S. dollar. The company does not hedge these risks and currently does not believe they are significant."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "risk_factor",
          "page": 100,
          "title": "Evaluation of Disclosure Controls and Procedures and Internal Control over Financial Reporting",
          "data": [
            {
              "key": "Evaluation Scope",
              "value": "Evaluated disclosure controls and procedures under management supervision, including CEO and CFO participation"
            },
            {
              "key": "Evaluation Date",
              "value": "December 31, 2022"
            },
            {
              "key": "Conclusion",
              "value": "Effective – controls were designed to ensure material information is disclosed timely and financial reporting is recorded, processed, summarized, and reported per SEC requirements"
            },
            {
              "key": "Internal Control Report",
              "value": "Management’s Report on Internal Control over Financial Reporting, based on the COSO 2013 Framework"
            },
            {
              "key": "Audit",
              "value": "Deloitte & Touche LLP audited the effectiveness of internal controls as of December 31, 2022"
            },
            {
              "key": "Risk Disclaimer",
              "value": "Noted inherent limitations in internal control that may not prevent or detect misstatements, with risk that controls may become inadequate if conditions change"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_guidance_updates": {
      "value": true,
      "elements": [
        {
          "type": "guidance_update",
          "page": 3,
          "title": "NEOGENOMICS, INC. FORWARD-LOOKING STATEMENTS",
          "data": [
            {
              "key": "Content Overview",
              "value": "This page contains the forward-looking statements disclaimer, outlining projections about future operations, financial position, revenues, and plans. It also references risk factors and includes trademark information."
            },
            {
              "key": "Forward-Looking Keywords",
              "value": "anticipate, believe, could, estimate, expect, forecast, goal, intends, may, plan, potential, project, will, would"
            },
            {
              "key": "Risk Factors Reference",
              "value": "Mentions 'Risk Factors Summary' in Part I, Item 1A of the Annual Report on Form 10-K as filed with the SEC."
            },
            {
              "key": "Trademarks",
              "value": "NeoGenomics, Genoptix, Clarient, Inivata, NEOARRAY, NEOLAB, NEOLINK, NEOSITE, NEOTYPE, CHART, COMPASS, FLEXREPORT, HEMEFISH, MULTIOMYX, NEOVUE, NEONET, NEOPATH, NEOSCORE, NEOACCELERATE, NEOENGAGE, NEOPIXEL, NEONUCLEUS, NEOUNIVERSITY, PATHSITE, QUICKPATH, TAM-SEQ, ETAM-SEQ, INVISION, INVISIONFIRST, INVISIONSCAN, INVISIONFIRST-LUNG, RADAR, NEORADAR; and marketing slogans 'TAKING CANCER PERSONALLY', 'UNIVERSAL FUSION EXPRESSION', 'NEOGENOMICS EUROPE', 'WHERE PASSION MEETS PURPOSE'."
            },
            {
              "key": "Update Disclaimer",
              "value": "States that forward-looking statements speak only as of the report date and are not updated to reflect future events or unforeseen circumstances."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 56,
          "title": "Goodwill — Clinical and Pharma Reporting Units — Critical Audit Matter",
          "data": [
            {
              "key": "Goodwill balance as of Dec 31, 2022",
              "value": "$522.8 million"
            },
            {
              "key": "Clinical reporting unit goodwill",
              "value": "$458.8 million"
            },
            {
              "key": "Pharma reporting unit goodwill",
              "value": "$64.0 million"
            },
            {
              "key": "Impairment assessment date",
              "value": "June 30, 2022"
            },
            {
              "key": "Fair value determination methods",
              "value": "Discounted cash flow model, market approach"
            },
            {
              "key": "Significant estimates required",
              "value": "Discount rates, future revenues, operating margins"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 64,
          "title": "COVID-19 Pandemic Update and CARES Act Effects",
          "data": [
            {
              "key": "Impacts of COVID-19 pandemic",
              "value": "Significant adverse impact on the Company’s results of operations, volume growth rates and test volumes in 2020, 2021, and 2022."
            },
            {
              "key": "Exit from COVID-19 PCR testing",
              "value": "Recorded a $6.1 million loss related to the exit from COVID-19 PCR testing."
            },
            {
              "key": "CARES Act grant income recognized",
              "value": "$7.9 million in grant income related to the CARES Act during the year ended December 31, 2020."
            },
            {
              "key": "Deferred social security taxes",
              "value": "Total accrued deferred social security taxes related to the CARES Act was $3.0 million as of December 31, 2021."
            },
            {
              "key": "ERTC provision",
              "value": "The Employee Retention Tax Credit (ERTC) encourages employers to retain employees on payroll."
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_regulatory_or_litigation_issues": {
      "value": true,
      "elements": [
        {
          "type": "regulatory_litigation",
          "page": 11,
          "title": "Government Regulation",
          "data": [
            {
              "key": "Diverse Workforce Commitment",
              "value": "A diverse and inclusive workforce positively impacts performance and strengthens culture."
            },
            {
              "key": "Rewards Package",
              "value": "Competitive salaries, performance-based bonuses, equity grants, healthcare benefits, retirement savings plans, paid family leave, paid time off, wellness programs, discounts, tuition reimbursement, Employee Assistance Program."
            },
            {
              "key": "Employee Development",
              "value": "Prioritizing training and development opportunities for employees."
            },
            {
              "key": "Government Regulation Overview",
              "value": "The laboratory industry is subject to extensive governmental regulation at the federal and state levels, and internationally."
            },
            {
              "key": "Licensure and Accreditation",
              "value": "Laboratories operate in various states and internationally, with necessary licenses and CLIA certification."
            },
            {
              "key": "Impact of CLIA Certification",
              "value": "Suspension or revocation of CLIA certification could adversely affect the Company."
            },
            {
              "key": "Quality Assurance Programs",
              "value": "Participation in CAP’s proficiency testing programs and maintenance of a Quality Management System."
            },
            {
              "key": "Compliance Verification",
              "value": "Compliance with standards is verified through periodic inspections by regulatory agencies."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 12,
          "title": "Compliance and Ethics Program",
          "data": [
            {
              "key": "Overview",
              "value": "The company has implemented a robust compliance and ethics program overseen by the Board of Directors."
            },
            {
              "key": " hotline ",
              "value": "The company provides a hotline for employees to report suspected violations."
            },
            {
              "key": "Compliance Committee",
              "value": "The Board of Directors has a Compliance Committee that meets regularly to discuss compliance issues."
            },
            {
              "key": "Regulatory Framework for LDTs",
              "value": "High complexity CLIA-certified laboratories like ours develop testing procedures known as Laboratory Developed Tests (LDTs)."
            },
            {
              "key": "FDA Regulatory Authority",
              "value": "The FDA has regulatory authority over instruments and tests used by clinical laboratories, with evolving oversight on LDTs."
            },
            {
              "key": "Recent Developments",
              "value": "The FDA's approach to LDTs has shifted significantly, particularly during the COVID-19 public health emergency."
            },
            {
              "key": "VALID Act",
              "value": "Congress has considered the VALID Act, which proposed amending the regulatory framework for LDTs."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 13,
          "title": "Regulatory Compliance and Anti-Kickback Laws",
          "data": [
            {
              "key": "Key Regulations",
              "value": "Federal Anti-Kickback Statute (AKS) and Eliminating Kickbacks in Recovery Act (EKRA)"
            },
            {
              "key": "Potential Violations",
              "value": "Significant penalties including fines, exclusion from government programs"
            },
            {
              "key": "International Regulations",
              "value": "U.S. Foreign Corrupt Practices Act (FCPA) and U.K. Bribery Act"
            },
            {
              "key": "Stark Law",
              "value": "Prohibits payments for certain health care services with financial relationships with referring physicians"
            },
            {
              "key": "Penalties for Violations",
              "value": "Civil and criminal penalties, exclusion from Medicaid, potential loss of licenses"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 14,
          "title": "Table of Contents – NEOGENOMICS, INC.: The False Claims Act and Regulatory Compliance",
          "data": [
            {
              "key": "Regulatory Framework",
              "value": "Discusses the federal False Claims Act, including its provisions on presenting false claims, fraudulent statements, and improper retention of overpayments."
            },
            {
              "key": "Litigation Risk",
              "value": "Highlights potential liability under the FCA, the use of whistleblower (qui tam) provisions, and the risk of exclusion from Medicare, Medicaid, and other federal healthcare programs."
            },
            {
              "key": "Compliance Measures",
              "value": "Emphasizes the Company’s efforts to maintain robust compliance programs, including auditing and monitoring activities to adhere to laws such as the AKS, Stark Law, and various state regulations."
            },
            {
              "key": "Additional Regulatory Considerations",
              "value": "Covers Medicare Payment Guidelines and Environmental Health and Safety regulations that impact billing practices and operational procedures."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 15,
          "title": "Company's Compliance with HIPAA and State Laws",
          "data": [
            {
              "key": "Health Insurance Portability and Accountability Act (HIPAA)",
              "value": "Protects individually identifiable health information from unauthorized use or disclosure."
            },
            {
              "key": "Compliance Status",
              "value": "Company believes it has taken necessary steps to comply with HIPAA regulations."
            },
            {
              "key": "Civil Monetary Penalties",
              "value": "HIPAA violations may be subject to criminal and civil penalties."
            },
            {
              "key": "California Consumer Privacy Act (CCPA)",
              "value": "Imposes privacy compliance obligations regarding the personal information of California residents."
            },
            {
              "key": "California Privacy Rights Act (CPRA)",
              "value": "Expanded CCPA protections, operational since January 1, 2023."
            },
            {
              "key": "Virginia Consumer Data Protection Act",
              "value": "Took effect on January 1, 2023."
            },
            {
              "key": "Colorado Consumer Protection Act",
              "value": "Will take effect on July 1, 2023."
            },
            {
              "key": "Connecticut Data Privacy Act",
              "value": "Will take effect on July 1, 2023."
            },
            {
              "key": "Utah Consumer Privacy Act",
              "value": "Will take effect on December 31, 2023."
            },
            {
              "key": "GDPR",
              "value": "European Union’s regulation for the protection of personal data."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 17,
          "title": "Risks Related to Government Regulation and Reimbursement",
          "data": [
            {
              "key": "Risk of Regulatory Changes",
              "value": "Regulatory changes, such as proposed government regulation of Laboratory Developed Tests, could require additional clinical trials, result in delays, increased costs, or failure to obtain necessary regulatory approvals."
            },
            {
              "key": "Impact of Healthcare Reform",
              "value": "Healthcare reform programs may impact pricing received for services."
            },
            {
              "key": "Compliance Costs",
              "value": "Failure to comply with laws and regulations could result in fines, penalties, and loss of licensure."
            },
            {
              "key": "Complexity of Third-party Billing",
              "value": "Third-party billing is complicated and incurs significant additional costs."
            },
            {
              "key": "Potential Penalties for Noncompliance",
              "value": "Failure to comply with laws related to fraudulent billing could result in exclusion from Medicare and Medicaid."
            },
            {
              "key": "Privacy and Security Compliance",
              "value": "Noncompliance with privacy laws could result in fines, penalties, and harm to the Company’s reputation."
            },
            {
              "key": "General Risk Factors",
              "value": "The COVID-19 pandemic may adversely affect operations and financial condition."
            },
            {
              "key": "Need for Additional Personnel",
              "value": "Dependence on key personnel and need for additional qualified hires for business success."
            },
            {
              "key": "Implementation of Business Strategy",
              "value": "Inability to implement business strategy could impair operations and profitability."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 29,
          "title": "Regulatory Compliance and Litigation Risk Factors",
          "data": [
            {
              "key": "Regulatory Environment",
              "value": "Company must comply with complex federal and state billing, coding, and documentation rules to avoid potential civil and criminal liabilities, including under the False Claims Act."
            },
            {
              "key": "Settlements and Lawsuits",
              "value": "Numerous laboratories have settled with government entities and faced civil actions from private payers related to noncompliance."
            },
            {
              "key": "Internal Investigation",
              "value": "The Company conducted an internal investigation (with outside counsel) into consulting and service agreements with respect to federal healthcare laws, and notified the OIG in November 2021."
            },
            {
              "key": "Accrued Liabilities",
              "value": "As of December 31, 2022, a reserve of $11.2 million was accrued for potential damages and liabilities related to federal healthcare program revenues."
            },
            {
              "key": "Potential Penalties",
              "value": "Noncompliance could result in significant civil monetary penalties, exclusion from Medicare/Medicaid programs, and other remedial actions."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "regulatory_litigation",
          "page": 97,
          "title": "Shareholder Class Action and Regulatory Investigation",
          "data": [
            {
              "key": "Court",
              "value": "United States District Court for the Southern District of New York"
            },
            {
              "key": "Case Caption",
              "value": "Daniel Goldenberg v. NeoGenomics, Inc., Douglas VanOort, Mark Mallon, Kathryn McKenzie, and William Bonello"
            },
            {
              "key": "Filing Date",
              "value": "December 16, 2022"
            },
            {
              "key": "Allegations",
              "value": "Claims of material misrepresentations and/or omissions in public disclosures in violation of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5"
            },
            {
              "key": "Affected Securities Period",
              "value": "February 27, 2020 to April 26, 2022"
            },
            {
              "key": "Reserve for Liabilities",
              "value": "$11.2 million"
            },
            {
              "key": "Regulatory Actions",
              "value": "Internal investigation leading to notification of the OIG; DOJ participation announced; ongoing interactions with regulatory authorities"
            },
            {
              "key": "Risk Disclosure",
              "value": "Uncertainty about the duration, scope, outcome and potential additional costs or liabilities from further investigations"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "regulatory_litigation",
          "page": 117,
          "title": "Arbitration and Notices Provisions",
          "data": [
            {
              "key": "Governing Law",
              "value": "This Agreement shall be governed and construed in accordance with the laws of the State of Florida."
            },
            {
              "key": "Jurisdiction and Venue",
              "value": "Executive consents to personal jurisdiction and venue in the Circuit Court and arbitration proceedings in Lee County, Florida (including Fort Myers for arbitration actions)."
            },
            {
              "key": "Arbitration",
              "value": "Any disputes between the Executive and the Company shall be resolved by arbitration under the American Arbitration Association’s Employment Arbitration Rules and Mediation Procedures before a single unbiased arbitrator."
            },
            {
              "key": "Notices",
              "value": "Notices must be provided in writing and are effective when delivered in person or by mailed postage prepaid to the specified addresses of the Executive or the Company."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 129,
          "title": "Notices in Agreement",
          "data": [
            {
              "key": "Content",
              "value": "Any notices provided for in this Agreement shall be in writing and shall be effective when delivered in person or deposited in the United States mail, postage prepaid, and addressed to the Executive at his or her last known address on the books of the Company or, in the case of the Company, to it at its principal place of business, attention of the Chairman of the Board, or to such other address as either party may specify by notice to the other actually received."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_strategic_restructuring": {
      "value": true,
      "elements": [
        {
          "type": "strategic_restructuring",
          "page": 68,
          "title": "Intangible Assets, Impairment, and Restructuring Disclosures",
          "data": [
            {
              "key": "Amortization Method",
              "value": "Intangible assets with determinable useful lives are amortized using the straight-line method."
            },
            {
              "key": "Impairment of Intangible Assets",
              "value": "For years ended December 31, 2022, 2021, and 2020 no impairment losses were recorded for intangible assets with indefinite useful lives."
            },
            {
              "key": "Long-Lived Assets Impairment Testing",
              "value": "Reviewed when events indicate possible impairment; impairment loss recognized if expected undiscounted pretax cash flows are less than carrying amounts."
            },
            {
              "key": "Restructuring Charge",
              "value": "In 2022, $0.7 million of impairment charges related to facility assets were recognized within restructuring charges."
            },
            {
              "key": "Goodwill Evaluation",
              "value": "Annual testing performed; for 2022, 2021 and 2020, no impairment losses were recorded despite qualitative and quantitative assessments."
            },
            {
              "key": "Contingent Losses",
              "value": "Accrued based on management judgment when conditions indicate probable impairment or liability with a reasonably estimable loss amount."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "strategic_restructuring",
          "page": 93,
          "title": "Note 14. Restructuring and Note 15. Income Taxes",
          "data": [
            {
              "key": "Restructuring Program",
              "value": "In 2022, the Company embarked on a restructuring program to improve execution and drive efficiency across the organization by identifying, prioritizing and executing operational improvements."
            },
            {
              "key": "Restructuring Charges Components",
              "value": "The program involved severance and other employee costs, Facility Footprint Optimization costs, and consulting and other costs."
            },
            {
              "key": "2022 Restructuring Charges Summary",
              "value": "According to the table titled 'Balance as of December 31, 2021', total restructuring charges incurred were 3,798 (in thousands): employee costs of 1,036, consulting costs of 2,762, and a facility-related impairment of 718. After cash payments and adjustments of -2,997, the final balance as of December 31, 2022 was 1,519, comprised of employee costs of 559 and consulting costs of 960, all classified as current liabilities."
            },
            {
              "key": "Future Restructuring Charges",
              "value": "The Company expects additional restructuring charges in 2023 of approximately $5.0 million, including about $2.0 million in severance and other employee costs, $2.0 million in Facility Footprint Optimization costs, and $1.0 million in consulting and other costs, with the restructuring activities anticipated to conclude by December 31, 2023."
            },
            {
              "key": "Income Taxes Note",
              "value": "Under Note 15, the CARES Act impacted several tax code provisions but did not result in any material adjustments to the Company’s income tax provision for the years ended December 31, 2022, 2021, and 2020, nor to its deferred tax assets as of December 31, 2022 and 2021."
            },
            {
              "key": "Income Taxes Breakdown",
              "value": "The accompanying table details (in thousands) the (loss) income before tax, with domestic and foreign components, as well as current and deferred tax expenses and benefits, highlighting significant losses and substantial deferred tax benefits, particularly in foreign operations."
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_supply_chain_disruptions": {
      "value": false,
      "elements": []
    },
    "has_esg_initiatives": {
      "value": false,
      "elements": []
    }
  },
  "currency": {
    "USD": 15,
    "EUR": 12,
    "AUD": 21,
    "CAD": 6,
    "ZAR": 14
  },
  "sha1": "f9736aa2f56c40b127bced09ce1c8e8cbf7aa0e3"
}